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Abstract of Dissertation 
 
 
 
 
  PROTEASOME REGULATION OF CASPASE-8: SIGNIFICANCE IN CANCER 
 
Anti-tumor therapeutic strategies based on combinations of chemotherapeutic agents with 
a death inducing ligand such as TNF-α Related Apoptosis Inducing Ligand (TRAIL), are 
directed towards selective and effective cancer cell apoptosis and enhanced therapeutic 
response. We previously demonstrated that proteasome inhibition sensitizes TRAIL 
resistant prostate cancer cells to TRAIL-mediated apoptosis via stabilization of the active 
p18 subunit of initiator caspase-8. The present study investigated the functional link 
between caspase-8 and the proteasome, by analyzing the impact of caspase-8 
ubiquitination and proteasomal degradation on the outcomes of the extrinsic apoptosis 
pathway in cancer cells. Caspase-8 ubiquitination status was assessed by polyubiquitin 
immunoprecipitation (IP) and fluorescent microscopy. Apoptosis induction in response to 
death receptor stimuli or proteasome inhibitor was evaluated using the Annexin 
V/Propidium iodide staining (PI). To determine the consequences of proteasome 
inhibition on caspase-8 stability, trafficking, and activity following death receptor 
activation, we used the TRAIL-resistant human prostate cancer LNCaP cells, and the 
caspase-8 deficient Neuroblastoma 7 (NB7) cells, as cellular models for reconstituting the 
non-cleavable mutant forms of caspase-8. Our findings demonstrate that the non-
cleavable forms of caspase-8 are capable of inducing apoptosis comparably to wild-type 
caspase-8 upon treatment with proteasome inhibitor and GST-TRAIL. Furthermore, 
caspase-8 processing into its active subunits preceded caspase-8 polyubiquitination, 
implicating caspase-8 processing as a potential regulatory mechanism, rather than a 
requirement for caspase-8 activation in apoptosis induction. The mechanistic control of 
caspase-8 by ubiquitination in cancer cells may have significant significance in bypassing 
mechanisms of therapeutic resistance in human tumors and optimization of anti-cancer 
treatment strategies in human tumors and optimization of anti-cancer treatment strategies. 
  
Keywords: Caspase-8, Proteasome inhibitor, TRAIL, Velcade, Apoptosis.  
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 Chapter 1 Background and Significance 
 
1.1. Signaling Pathways in Cancer Development 
Cancer is a disease where normal healthy a cell undergoes oncogenesis through 
the accumulation of a series of genetic and epigenetic mutations that results in the 
deregulation of critical regulatory pathways and ultimately giving rise to tumorgenesis 
(Hanahan and Weinberg, 2000). As a result of uncontrolled signaling pathways, tumor 
cells acquire new characteristics (Fig. 1.1.1) such as the ability to invade surrounding 
tissues, recruit their own vasculature, (termed angiogenesis) and metastasize.  Several 
major pathways are altered, including the proliferation, cell cycle progression, and pro-
survival pathways which are induced while the apoptotic pathways are down-regulated.    
These pathways intersect one another at some point in their respective signaling cascades.  
Cell cycle consists of several phases; G0, G1, S, G2, and Mitosis. These phases are 
regulated by various cyclins and CDK (cyclin dependant kinases) and progression from 
one phase to another is dependent on specific checkpoints (Fig 1.1.2). One of the most 
heavily studied checkpoints is the G1/S checkpoint which allows a cell to enter S phase 
(DNA replication) (Vermeulen et al., 2003).  A very critical player at this checkpoint is 
p53 (notoriously known as the Guardian of the Genome) due to its role in rescuing 
damaged DNA, via up-regulation of downstream effectors, such as p21 (induces cell 
cycle arrest) and PUMA which blocks anti-apoptotic players leading to apoptosis 
induction (Fig 1.1.2) (Haupt et al., 2003; Malumbres and Barbacid, 2009).   Cell cycle 
regulation via p53 can primarily be abrogated by loss-of-function mutations, losing p53 
activity allows for the cell to replicate regardless of DNA integrity and increases 
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apoptosis resistance (Wang et al., 2011).  Additional mechanisms of p53 down-regulation 
involve the over-expression of MDM2, an E3 ligase that mediates the polyubiquitination 
of p53 resulting in its degradation. Over-expression of MDM2 ensures rapid degradation 
of p53 leading to diminished if not abolished p53 activity and unregulated cell cycle 
progression (Wasylyk et al., 1999). Proteasome inhibitors, agents that block protein 
degradation mediated by 26S proteasome, have been shown to stabilize p53 and restore 
p53 mediated apoptosis (Williams and McConkey, 2003). Established chemotherapeutic 
agents such as Mitomycin C or Doxorubicin are chemotherapeutic agents that are used to 
induce cell cycle arrest in a variety of epithelial cancers.  These agents work to either 
cross link DNA (Mitomycin C) or bind directly to the DNA intercalating into the double-
helix strands causing the DNA to become rigid and break (Doxorubicin) (Celli and 
Jaiswal, 2003). Although these agents are effective they aren’t specific to cancer cells and 
damage surrounding healthy normal cells, tissues, and organs such as kidney (Mitomycin 
C) or the heart (Doxorubicin) (Bugger et al., 2011; Kumari et al., 2009).  Treatment of 
MCF-7 breast cancer xenographs with a combination of Mitomycin C with curcumin 
significantly decreased Mitomycin C related side effects (Zhou et al., 2009).  
Strategies involved with overcoming the toxic side effects of Doxorubicin by 
changing the mode of Doxorubicin delivery by encapsulating the drug in titanium 
nanoparticals which showed promising results (Chen et al., 2011).  Circumventing the 
caveats associated with systemic toxicities of these chemotherapeutics involved 
examining other pro-survival pathways, such as the AKT signaling pathway which can 
also impact cell cycle regulation and growth arrest. 
3 
 
The AKT pathway is activated through binding of growth factors to their cognate 
tyrosine kinase receptors which then carry out the signal transduction through the 
interplay between SRC, Phosphatidylinositol-3 Kinase (PI3K) and Phosphotidylinositol-
4, 5-bisphosphate (PIP2), and Phosphotidylinositol-3, 4, 5-triphosphate (PIP3) and a 
critical regulatory molecule, PTEN (Fig. 1.1.3) (Fruman et al., 1998; Hennessy et al., 
2005; Hiles et al., 1992). PTEN, a phosphatase, regulates AKT activation because it 
dephosphorylates and converts PIP3 to PIP2 thus preventing PIP3 -- AKT interaction 
(Sansal and Sellers, 2004). AKT is a kinase that phosphorylates several different targets 
such as mTOR, IKK (an inhibitory binding protein that prevents NFκB activation), and 
cell cycle inhibitors, (p21, p27).  In cancer activation of the AKT pathway can become 
aberrant because of a variety of mutations that can occur within PI3K, AKT, and PTEN 
(Skeen et al., 2006). One of the most detrimental and oncogenic potential promoting 
mutations are those that render these molecules constitutively active. Constitutively 
active PI3K can lead to the increase in the conversion rate of PIP2 to PIP3 favoring PIP3 
production leading to increased AKT activation (Kang et al., 2005).  
 A specific AKT mutation, E17K in either AKT1 or AKT3 leads to constitutive 
activation and promotes increased trafficking to the plasma membrane (Carpten et al., 
2007; Davies et al., 2008).  PI3K and AKT activating mutations are deleterious for the 
cell; however, another mechanism that can elevate AKT activity to supra-physiological 
levels and contribute to oncogenesis is the loss of PTEN, a critical regulator of AKT 
activation. Interrogation of the signaling events dictated by AKT, mTOR, and PI3K has 
lead to the development of a powerful class of pharmacologic inhibitors. The most 
promising class of AKT inhibitors are the lipid based inhibitors which essentially inhibit 
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AKT binding to the plasma membrane. Perifosine has emerged as one of the most 
promising AKT inhibitors and has been through several phase II clinical trials 
(Brachmann et al., 2009; Dubrovska et al., 2009; Ernst et al., 2005; Rahmani et al., 2005).  
The mTOR inhibitors include Rapamycin and its derivatives, such as CCI-779, blocks 
mTOR function through similar mechanisms that primarily involve binding to the co-
factor FKBP and together, Rapamycin and FBKP bind to mTOR and inhibit activity 
(Faivre et al., 2006).  PI3K inhibitors like Wortmannin or its derivative, LY294002 bind 
covalently to PI3K to inhibit its kinase activity (Maira et al., 2009b). These agents 
however, lack specificity and new carefully designed inhibitors such as CAL-101 
(Calistoga) have shown promising results in clinical trials (Maira et al., 2009a; Maira et 
al., 2009b; Markman et al., 2010) which are on-going at Clearview Cancer institute 
(2012). PI3K inhibitors exhibit higher efficacy combination with existing 
chemotherapeutic agents such as, an AKT or mTOR inhibitors because these 
combinations block two pathways, eliminating individual pathway activity as well as 
preventing activation of alternate or redundant non-AKT mediated pathways activated 
through PI3K (Courtney et al., 2010). 
PTEN is the direct inhibitor of AKT because it converts AKT activating PIP3 into 
PIP2, which does not activate AKT.  PTEN studies have revealed that PTEN may be 
down-regulated either through inactivating mutations, gene deletions, and 
phosphorylation of PTEN by CK2 have the same result, persistent AKT signaling that 
contributes to tumor formation (Vazquez et al., 2001; Vazquez et al., 2000) PTEN loss 
has been associated with several cancers at the advanced stage of disease, including 
prostate cancer(Stahl et al., 2003).  PTEN mutations have been linked with aggressive 
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androgen dependant or androgen independent (termed castration recurrent) prostate 
cancer (Bismar et al., 2012; Yoshimoto et al., 2012) and evidence suggests that 
oncogenesis results due to the loss of AKT and cell cycle regulation (Faivre et al., 2006; 
Sircar et al., 2009; Squire, 2009; Suzuki et al., 1998; Vlietstra et al., 1998).  
 
1.2 Prostate Cancer 
Prostate cancer is one of the most prevalent causes of cancer releated death in 
males with several risk factors, such as age, race, and diet contributing towards prostate 
cancer development and progression (Fedewa et al., 2010; Jemal et al., 2010). Regulation 
of androgen signaling via the androgen receptor (AR) is critical to maintaining prostate 
homeostasis. The androgen axis involves conversion of testosterone, synthesized by the 
prostate, which is then converted into 5α-dihydrotestosterone (DHT) by 5α-reductase.  
Once testosterone is converted into DHT it can then bind with AR and both ligand and 
receptor translocate to the nucleus to activate subsequent signaling pathways (Heinlein 
and Chang, 2002).  When prostate cells undergo tumorgenesis they take on different 
molecular characteristics, one of the more prominent changes is the up-regulation of 
androgen receptor either through gene amplification or through other processes leading to 
over-expression of the receptor (George and Moul, 2012).  Up-regulation of the AR leads 
to increased activation of the AR pathways ultimately activating proliferation pathways, 
inhibiting apoptosis, or further sensitizing prostate cancer cells to growth factors stimuli 
such as EGFR (Niraula and Tannock, 2011; Stanbrough et al., 2006). Currently the best 
therapy for treating primary prostate cancer is castration induced androgen deprivation, 
which involves chemically depleting androgens in the prostate androgen inhibitors such 
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as abiraterone (Nelson et al., 2011).  Aside from abiraterone, there are other agents being 
tested in clinical trials such as MDV3100 which is a competitive inhibitor blocking AR-
androgen signaling (Scher et al., 2010). 
Although androgen depletion strategies are effective at reducing tumor burden, 
there are unfortunate cases where prostate cancer can reoccur. What makes this recurrent 
prostate cancer difficult to treat is because these prostate cancer cells can become 
androgen independent rendering androgen ablation ineffective. One strategy to treat 
recurrent prostate cancer involves using a class of microtubule targeting 
chemotherapeutic agents called taxanes. These agents target microtubules, a component 
of the cellular cytoskeleton, and stabilize microtubules thereby preventing microtubule 
reorganization, and disrupting kineticore formation during mitosis (Giannakakou et al., 
2000; Jordan et al., 1993).   Taxanes have limited efficacy as prostate cancer can be very 
resistant to taxane therapies. Proposed mechanisms conferring taxane resistance involve 
either microtubule mutations that prevent drug binding or the cell itself pumps out the 
taxane through p-glycoprotein pumps at the cellular membrane (Madan et al., 2011). In 
addition to prostate cancer, taxanes have been used against other solid tumors such as 
breast, lung, ovarian, and esophageal cancers (Ehrlichova et al., 2005a; Ehrlichova et al., 
2005b; Ramalingam and Belani, 2002).  
Although some of the agents described above have proven effective against 
specific cancers they have their own caveats such as, adverse side-effects but more 
importantly, tumors, either primary or refractory, possess either innate or acquired 
resistance to these agents rendering them ineffective. Therefore investigators have sought 
to over-come tumor resistance by interrogating different combinations of therapeutic 
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strategies.   Alternative approaches involve inducing or restoring the apoptotic pathways 
through a variety of other agents such as staurosporin, etoposide, and a new emerging 
class of apoptosis inducing agents, the death ligands such as TNF-α Related Apoptosis 
Inducing Ligand (TRAIL) an agent that will be discussed further in subsequent sections.  
 
1.3 Mechanisms of Apoptosis Regulation 
Apoptosis (programmed cell death) plays a critical role in regulating cell growth 
and tissue development.  Therefore one of the tumor survival mechanisms is to deactivate 
the cell’s ability to undergo any form of apoptosis mediated through the up-regulation of 
anti-apoptotic players as well as the down-regulation pro-apoptotic players. Since loss of 
apoptosis leads to tumor initiation, growth, and progression (Lowe and Lin, 2000), 
exploitation of apoptosis mechanisms can lead to developing new anticancer strategies, 
that can effectively impair the tumorgenic process.  
Each pathway of apoptosis is activated by different triggers such as cell-
detachment (Anoikis Fig 1.3.1), mitochondrial signals (intrinsic pathway), or death 
ligands (extrinsic pathway), (Fig 1.3.1-1.3.3). A mechanism designed to protect against 
cellular metastasis is anoikis, which is an apoptosis program that is induced upon the loss 
of critical protein interactions between the cell and the extracellular matrix.  The major 
players and pathways involved with anoikis are integrin, focal adhesion, and growth 
factors (IGF-1) interactions as well as the JNK pathway, and caspase activation signaling 
events (Zhan et al., 2004). Anoikis plays a role in all tissue and cell types preventing the 
detachment and migration of epithelial cells (Frisch and Screaton, 2001; Zhan et al., 
2004). Examples include some shedding of colon epithelial cells (Bullen et al., 2006; 
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Strater et al., 1996) and mammary gland reduction (Haenssen et al., 2010; Lund et al., 
1996). Anoikis is initiated when adherent cells detach from the basement membrane, 
more specifically, the loss of integrin (either α5 or β3) signaling with the focal adhesion 
points (Frisch and Ruoslahti, 1997; Vachon, 2011).  Upon cell detachment and loss of 
integrin signaling the apoptotic pathways are activated (Fig. 1.2.2). Cancer cells can 
inhibit anoikis through a variety of mechanisms such as over-coming the loss of FAK 
(focal adhesion kinase), acquiring mutations in FAK that induce anoikis inhibitory 
mechanisms (Zouq et al., 2009) or influence from the external cellular environment may 
provide signals that result in shutting down the apoptotic pathways (Rennebeck et al., 
2005).  
There are two pathways of classical apoptosis, the intrinsic and extrinsic pathway. 
The intrinsic pathway is under heavy regulation by several different types of molecules 
that can be separated into two main classes, anti-apoptotic proteins such as the XIAP 
(inhibitors of apoptosis), BCL family proteins such as BCL2, BCL xl or the pro-apoptotic 
proteins which include, BCL family members; BAX, BAD, BID, SMAC, and Diablo are 
activated through signaling events that lead to mitochondrial outer membrane 
permeabilization (MOMP). Cytochrome C is released, binds with APAF-1 and caspase-9 
to form the apoptosome (Siu et al., 2008). Upon apoptosome formation, caspase-9 
becomes catalytically active and acts on downstream targets such as executioner caspases 
3 and 7 (Fig. 1.3.2) (Ohtsuka et al., 2003). 
Tumor cells can inactivate cell death signaling programs, by engaging anti-
apoptotic mechanisms involving the up-regulation of apoptotic suppressors, (Bcl2, Bclxl) 
and/or through the down-regulation of critical apoptosis inducing players such as the 
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caspase family (2, 4, 6, 8, 9, 10, 12) (Elmore, 2007).  Mechanisms that inhibit the 
intrinsic pathway of apoptosis are interconnected with activities of the AKT (Fig 1.1.3) 
and NFκB (figure 1.3.4) pathways.  Therefore, should the AKT pathway be up-regulated 
through any means previously discussed, then ultimately this would lead to an inhibition 
of the intrinsic pathway of apoptosis as AKT signaling promotes BCL2 and BCLxl 
activity while inhibiting BAX and BAD players involved with inducing apoptosis (Tait 
and Green, 2010) (Fig. 1.3.2). Blocking BAX and BAD activity can prevent MOMP from 
opening, thus preventing Cytochrome C release, and consequentially inhibiting 
apoptosome formation.  Another family of anti-apoptotic proteins that can inhibit both 
the intrinsic and extrinsic pathways is the Inhibitors of Apoptosis (IAP) which have two 
arms, the cIAP or X-linked IAP (XIAP).  The IAP family consists of E3 ligases that can 
block apoptosome formation through binding directly to APAF-1 or caspase-9, thus 
inhibiting caspase-9 activation (Deveraux et al., 1998; Sun et al., 2009).  XIAP can also 
bind directly to caspase-3 preventing its activation, and in-addition to blocking activation 
XIAP can facilitate the transfer of ubiquitin, thereby tagging the caspases for degradation 
by the 26S proteasome (Schile et al., 2008).   
In addition to BCL and IAP family involvement with apoptosis inhibition there 
are also mutations acquired in the pro-apoptotic machinery itself and the most notable 
mutations are those that occur within the caspase family.  For example, Srinvisula et al, 
identified caspase-9b, a caspase-9 mutant that lacks the large active subunit and 
established that caspase-9b acts in a dominant negative fashion preventing caspase-3 
activation (Srinivasula et al., 1999).  Moreover, Park et al; identified several gene 
polymorphisms that give rise to altered forms of caspase-9 that impair caspase-9 activity 
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and thereby block apoptosis induction (Park et al., 2006). Post-translational modification 
of caspase-9 phosphorylation at Thr 129 mediated as a result of CDK-1 and cyclin B in 
cell cycle (Allan and Clarke, 2009) also prevents caspase-9 recruitment to the 
apoptosome blocking caspase-9 activation. Regardless of how caspase-9 is impacted, if 
this caspase fails to become active then the subsequently executioner caspases 3, 7 
activation is blocked and so is apoptosis activation through the intrinsic pathway (Bratton 
and Salvesen, 2010; Janssen et al., 2007).  
The extrinsic pathway (also referred to as the death receptor pathway) involves 
the induction of apoptosis through the activation of death receptors via death ligands such 
as Tumor Necrosis Factor-α (TNF-α), FAS, and TNF Related Apoptosis Inducing Ligand 
(TRAIL)(Wallach et al., 2008). While FAS and TRAIL strictly activate the extrinsic 
pathway mediated apoptosis, TNF-α can play two different roles, although this molecule 
is capable of inducing apoptosis, TNF-α is also capable of activating pro-survival 
pathway.  TNF-α, is a pro-inflammatory cytokine that is a part of the TNF superfamily.  
TNF-activation impacts several critical cellular pathways some of which include cellular 
proliferation, differentiation, and apoptosis (Naude et al., 2011). More specifically, TNF-
α binding to its cognate receptor can lead to the formation of two separate complexes, 
Complex 1 which can lead to the induction of either the Nuclear factor of kappa B 
(NFκB) pathway (pro-survival) (Wajant and Scheurich, 2011) or Complex 2 which 
activates the apoptotic pathway mediated primarily through FADD and caspase-8 
activation (Tran et al., 2009; Wang et al., 2008) (Fig. 1.2.4). 
Complex 1 mediated NFκB induction is initiated through the binding of TNF-α to 
its cognate receptor TNFR-1 which then leads to the recruitment of two adaptor proteins 
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TNF Receptor-Associated protein with a Death Domain (TRADD) and Receptor- 
interacting protein 1 (RIP1) (Chen, 2005). Upon binding of TRADD another adaptor 
molecule, TNF Associated factor-2 (TRAF), followed by the recruitment of cIAP 
(cellular inhibitors of apoptosis), as well as Ubc6 and Ubc13 (E2 ubiquitin conjugating 
enzymes) (Fukushima et al., 2007; Wu et al., 2005) to form Complex 1.  Once Complex 1 
is formed, key signaling events are activated and TRAF2 is capable of being either K63 
or K48 linked polyubiquitinated.  TRAF2 is phosphorylation by PKC results in K63 link 
polyubiquitination (Li et al., 2006; Li et al., 2009) and once K63 linked 
polyubiquitinated, TRAF 2 can mediate NFκB activation through signaling cascades 
involving the IKK complex.  Should TRAF2 become K48 linked polyubiquitinated this 
leads to degradation by the proteasome (Habelhah et al., 2004; Shi and Kehrl, 2003). 
In addition to TRAF2 posttranslational modifications, RIP-1 is also subjected to 
K48 or K63 polyubiquitination.  TRAF2, cIAP, and Ubc13 function in concert to 
facilitate K63 linked polyubiquitination of RIP1 (Wicovsky et al., 2009).  K63 linked 
polyubiquitination of RIP-1 leads to activation of Tak1/TAB complex to activate the IKK 
complex, which interestingly enough can also be activated by K63 modified TRAF2 
(Habelhah, 2010). The IKK complex consists of several components, IKK α, IKK β, and 
IKK γ, this kinase complex phosphorylates the Inhibitor of Kappa B molecule (IκB-α) 
(Ea et al., 2006).  IkB α, is a bound inhibitor of NFκB that functions to prevent nuclear 
import of NFκB into the nucleus. However, once IκB-α is phosphorylated, it is 
susceptible to K48 linked polyubiquitination and is degraded by the 26S proteasome thus 
releasing NFκB inhibition. Once released, NFκB can translocate into the nucleus and 
binds to its respective DNA binding sites leading to gene activation (Mathes et al., 2008).  
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NFκB up-regulates several different gene types, such as inflammatory response (Bond et 
al., 2001) pro-survival genes, BCL family, caspase-8 inhibitor c-FLIP,  cIAP and 
angiogenesis players and proliferation genes, cyclin D1 and MYC (Papa et al., 2006; 
Puszynski et al., 2009)(Nishikori, 2005). Interestingly enough, proteasome inhibition can 
impede the NFκB pathway because, it prevents the proteasome degradation of IκB-α thus 
leading to decreased activation of NFκB (Li et al., 2001; Markovina et al., 2008).  
The induction of apoptosis through Complex 2 of the TNF-α pathway is induced 
through several different events, however, the critical events for apoptosis induction 
involve the depletion of c-Flip and/or c-IAP expression levels, as well RIP1 kinase  
phosphorylation (Biton and Ashkenazi, 2011; Rangamani and Sirovich, 2007). Once 
phosphorylated, RIP1, Fas Associated Death Domain (FADD) and initiator caspase-8 are 
recruited thus assembling complex 2. Once Complex 2 is formed, caspase-8 is processed 
and can then cleave its downstream targets, executioner caspases 3, 7 which can then 
carry the apoptosis program (1.3.4)(Yuan and Kroemer, 2010).  
Recent exciting new insights into the mechanism of apoptosis induction through 
the formation of the Ripoptosome, a 2mD apoptosis signaling complex composed of RIP-
1, FADD, and caspase-8 that forms independent of both intrinsic and extrinsic pathway 
activation (Fig. 1.3.5) (Tenev et al., 2011).  This complex assembles when cIAP 
expression levels are depleted, either through up-regulation of SMAC a direct inhibitor of 
cIAP or through SMAC mimetics or other chemotherapeutics such as etoposide, which is 
a topoisomerase II inhibitor used to treat a variety of solid tumor cancers. In-addition to 
inducing DNA breaks etoposide has been shown to down-regulate cIAPs (Bertrand and 
Vandenabeele, 2011; Feoktistova et al., 2011; Imre et al., 2011; Tenev et al., 2011).  The 
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ability to form this apoptosis inducing complex, can serve as a powerful tool for 
developing anti-cancer strategies because an agent (or combination of agents) could 
induce apoptosis, while bypassing the normal requirements for apoptosis induction.  
Bypassing the “traditional” requirements, would provide opportunities to circumvent the 
anti-apoptotic approaches tumor cells up regulate to ensure its survival. Additional 
studies have provided evidence suggesting that the Ripoptosome is also capable of 
inducing necroptopsis (programmed necrosis) (Declercq et al., 2001; Oberst et al., 2011) 
mediated through RIP3 signaling events as opposed to RIP1 (Feoktistova et al., 2012).  
The extrinsic pathway of apoptosis is abrogated through several mechanisms, 
including the up-regulation of the Inhibitors of Apoptosis proteins such as cIAP or XIAP.  
Up-regulation of these inhibitors of apoptosis molecules will drive the TNF-α pathway 
towards NFκB activation in the same manner as described above.  Apart from inhibition 
by the IAP family, recent studies published data showing that IL-6/STAT3 signaling can 
override apoptotic signals by activating pro-survival, (BCL2, BCLxl) as well as cyclin D 
(Li et al., 2012). TRAIL and FAS mediated apoptosis pathways are very similar to one 
another in that these trimeric ligands bind their specific cognate receptors to induce 
apoptosis.  TRAIL binds to the DR 4/DR5 receptors which leads to receptor 
oligomerization in the plasma membrane, some groups suggest that these receptors 
oligomerize in the lipid rafts of the plasma membrane (Mollinedo and Gajate, 2006; Song 
et al., 2007). Once the receptors oligomerize there is recruitment of adaptor protein Fas 
Associated Death Domain (FADD). FADD binding to the TRAIL receptor leads to 
initiator caspase-8 recruitment to form the death inducing signaling complex (DISC). 
Following DISC formation procaspase-8 becomes autocatalytically active, once active 
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caspase-8 is processed into the active p18 and p10 subunits via two cleavage events. 
Once processed the p18 and p10 dimers can oligomerize with other p18/p10 dimers to 
form active heterotetramers, that cleaves specific targets such as HDAC7 (Scott et al., 
2008), and executioner caspases (3 and 7) which fully induce the apoptotic response (Fig. 
1.3.3) (Diessenbacher et al., 2008; Zhang et al., 2007).   
During onocogenesis, tumor cells utilize a variety of mechanisms to inactivate the 
extrinsic pathway of apoptosis; one mechanism in particular involves the down-
regulation of death receptor expression or up-regulation of decoy receptors (Matsuda et 
al., 2005). It could be argued that loss of receptor expression would have a more 
profound effect on FAS and TRAIL compared to TNF-α. A tumorgenic cell prefers, that 
TNF-α receptor expression because this enables the activation of the NFκB and other pro-
survival pathways. Tumors down regulate the FAS and TRAIL receptors to inhibit the 
extrinsic pathway activation.  With respect to TRAIL, its cognate receptors consist of  
Death Receptor 4 or 5 (DR4, 5), as a protective measure, the cell also expresses decoy 
receptors Dcr1 and Dcr2 as an effort to prevent unintended apoptosis induction through 
TRAIL binding to the death receptors (Almasan and Ashkenazi, 2003; LeBlanc and 
Ashkenazi, 2003).  In addition to receptor or decoy mediated inhibition, the extrinsic 
pathway can also be inhibited through similar mechanisms that inhibit the intrinsic 
pathway, such as over-expression of BCL2, BCLxl, cIAP and XIAP anti-apoptotic 
proteins (Fulda et al., 2002; Hinz et al., 2000; Newsom-Davis et al., 2009) 
TRAIL enables an attractive therapeutic platform for development as a single 
chemotherapeutic agent or in combination with existing chemotherapeutics. Several 
investigators have studied TRAIL using different mouse models which have 
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demonstrated that TRAIL preferentially targets cancer cells and not healthy non-
neoplastic cells (Mitsiades et al., 2001; Plasilova et al., 2002).  This specificity renders 
TRAIL a valuable chemotherapeutic agent due to the limited side effects and TRAIL 
protein can be synthesized via standard protein purification methods.  However, TRAIL 
is very unstable in solution therefore, in order to use TRAIL for lab studies, investigators 
have conjugated the TRAIL protein with protein tags, for example, our lab conjugated 
GST-tag to the C-terminal domain of TRAIL.  TRAIL C-terminal conjugation can extend 
TRAIL half-life by 11 hours allowing it to be used for in-vitro and in-vivo experiments 
(Thorpe et al., 2008b).  For clinical trial and treatment applications companies, like 
Human Genome Sciences (Rockville MD, USA) have generated TRAIL receptor 
activating antibodies with the intent to extend TRAIL half-life. These companies were 
successful in generating TRAIL receptor antibodies as evidenced by several in-vitro and 
in-vivo studies that analyzed TRAIL antibodies, Mapatumumab and Lexatumumab 
indicating these antibodies are functionally capable of inducing apoptosis (Belyanskaya 
et al., 2007; Huang and Sheikh, 2007; Luster et al., 2009).  
Additional studies have combined TRAIL with existing chemotherapeutic agents 
in pre-clinical studies, some of these agents include phytoshingosine (impacts 
sphingolipid metabolism) (Choi et al., 2007), Doxorubicin (Guo et al., 2011; Wu et al., 
2002), docetaxel (Yoo et al., 2008) and paclitaxel (Mielgo et al., 2009) all of which have 
shown promising results suggesting that TRAIL should be investigated further as a 
chemotherapeutic strategy.  In-progress is a clinical trial studying the combination of 
TRAIL and VEGF inhibitor, Bevacizumab, (Clinical trial identifier, NCT00508625). 
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Emerging involve testing TRAIL in combination with Proteasome inhibitor Velcade in 
both the pre-clinical and clinical settings
113, 114
.   
 
1.4 Caspases Key Apoptosis Regulators 
Caspases are a family of cysteine proteases that play roles in several different 
pathways, including, inflammatory, development, and apoptotic pathways. Although each 
caspase serves a different purpose there are several similarities in cleavage, the proform 
is cleaved into a large catalytically active subunit and a small subunit as shown for the 
critical apoptotic caspases (1.4.1). Caspases 1 and 5 play a role in inflammation (Bian et 
al., 2011; Yu and Finlay, 2008).  ER stress response pathways, Unfolded protein response 
(UPR), or ER associated degradation (ERAD) are mediated through caspase-4, eventually 
leading apoptosis induction through the intrinsic pathway. 
The endoplasmic reticulum (ER) is a critical cellular organelle whose primary 
function is to ensure proteins are properly folded before export into the golgi apparatus 
and respective regions of the cell (Anelli and Sitia, 2008). The protein folding machinery 
consists of several components that work in concert to ensure proper protein folding.  
However, when the ER is overwhelmed with polypeptides that are incapable of being 
folded correctly, three sensors, IRE-1, PERK, and ATF6 trigger the unfolded protein 
response (UPR) (Shuda et al., 2003).  If these pathways are incapable of clearing the ER 
of these misfolded proteins and the high level of ER stress persists, CHOP expression is 
markedly increased.  An increase in CHOP expression leads to a down-regulation in pro-
survival BCL family members, BCL2 and BCLxl allowing for BAX and BAD expression 
and activity to increase and thereby leading to intrinsic pathway activation (Fig. 1.4.2 ) 
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(Lai et al., 2007).   Alternative intrinsic pathway induction mechanisms can involve the 
activation of caspases 2, 4, and 12 (Bian et al., 2009; Hitomi et al., 2004) which then 
contributes to the processing of caspase-9 either through disrupting the mitochondria(Jing 
et al., 2012) or through APAF-1 independent mechanisms (Fig 1.3.2) (Rao et al., 2002).  
Caspase-2 has been implicated to induce intrinsic pathway apoptosis either through Bid 
cleavage thus leading to intrinsic pathway activation via the opening of the MOMP 
releasing Cytochrome C facilitating apoptosome formation (Upton et al., 2008) or 
through caspase-2, PIDD, and adaptor protein RAIDD bind and form piddosome (Tinel 
and Tschopp, 2004)  Compared to healthy cells, tumor cells have a marked increase in 
protein synthesis as well as an over-production of misfolded or unfolded protein in the 
ER, resulting in extremely high ER stress levels. Therefore investigators have developed 
strategies to induce apoptosis by further elevating ER stress using chemotherapeutics 
such as Velcade (Verfaillie et al., 2010). Velcade is designed to block the 26S 
proteasome and once inhibited, UPR response mechanisms become impaired leading to 
apoptosis induction (Dong et al., 2009; Obeng et al., 2006).  To circumvent proteasome 
inhibition, cells activate lysosomal pathways as an alternate mechanism for protein 
clearance. Exploitation of this mechanism as an anti-cancer strategy involves the use of 
Velcade in combination with lysosomal inhibitor, Tubacin (an HDAC6 inhibitor that 
block aggresome formation) and reports have demonstrated that together these agents are 
capable of apoptosis induction (Bolhuis and Richter-Landsberg, 2010; Hideshima et al., 
2005; Rodriguez-Gonzalez et al., 2008).  
The intrinsic pathway is a mitochondrial mediated pathway of apoptosis that can 
be activated through several different types of signals.  The major players involved with 
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apoptosis induction, most notably, Cytochrome C, APAF-1, and caspase-9 which 
associate with one another to form the apoptosome. Once the apoptosome is formed, 
caspase-9 is then processed into its active p37 and p19 subunits (Rodriguez and 
Lazebnik, 1999) and capable of cleaving executioner caspases 3/7 (Figs. 1.3.2, 1.4.1).  
Cancer circumvents intrinsic pathway activation by a variety of mechanisms, one of them 
involves the down-regulation of caspase-9 activation which is mediated with the 
involvement of the BCL family members such as BCL2 and BCLxl or XIAP binding as 
described previously above, or through the prevention of apoptosome formation either 
through pro-survival signals that prevent the opening of the mitochondria thus preventing 
the release of Cytochrome C into the cytosol (Hu et al., 1998; Shiozaki et al., 2003).  
Tumors transected from patients ranging from a variety of cancer types including, 
colorectal, lung, and gastric tumors, revealed several different point mutations in caspase-
9 that render this caspase inactive and incapable of inducing apoptosis (Soung et al., 
2006).   
Both the intrinsic and extrinsic pathways converge at the same point, the cleavage 
of executioner caspases 3 and 7 (Figs. 1.3.2, 1.3.3). Executioner caspases 3, 7 (also 
termed effector caspases) are processed into active subunits (Fig. 1.3.1) and responsible 
for the execution of the apoptosis program through the cleavage of ICAD (Caspase-
activated DNase) which then translocates to the nucleus and cleaves DNA (Larsen et al., 
2010).  Caspase-3 propagates and amplifies the apoptosis signal through a loop that leads 
to caspase-9 cleavage thus further propagating the apoptotic cascade (Blanc et al., 2000; 
Fujita et al., 2001).  Loss of caspase-3 expression has been suggested to play a role in 
promoting oncogenesis (Devarajan et al., 2002)  Caspase-7 is down regulated in cancer 
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and investigators have suggested to use this lack of caspase-7 expression as a marker for 
colon cancer (Palmerini et al., 2001). 
Caspase-10 is an initiator caspase that is recruited to the DISC like caspase-8. 
Caspase-10 has been extensively studied and the data from these studies have drawn 
mixed conclusions regarding its apoptosis inducing capabilities. Reports have provided 
evidence that show caspase-10 is capable of inducing apoptosis in caspase-8 deficient 
cells (Kischkel et al., 2001; Krug, 2012). In particular, pediatric neuroblastoma tumors 
are caspase-8 deficient however caspase-10 is sufficient to induce apoptosis (Lafont et 
al., 2010).  However, other studies have reported that caspase-10 lacks the capacity to 
induce apoptosis in the absence of caspase-8 in other cancer types; caspase-8 remains the 
critical initiator caspase responsible for extrinsic pathway activation (Sprick et al., 2002).   
 
1.5. Caspase-8 in Death Receptor Independent and Dependant Pathways 
Of mechanistic significance is growing evidence implicating caspase-8 having a 
role in non-apoptotic signaling pathways. Stupack et al, (2009) reported that caspase-8 in 
neuroblastoma cell lines plays a role in mediating focal adhesion complex formation and 
cellular migration (Barbero et al., 2009).  Earlier studies described a pathway that was 
nearly identical to the anoikis pathway, termed Intergin Mediated Death (IMD), although 
interestingly enough anoikis was not identified as the main form of apoptosis in this study 
(Stupack et al., 2006).   
Further studies by the group revealed that caspase-8 is phosphorylated on 
Tyrosine residue 380 via SRC kinase activity (Barbero et al., 2008); moreover it was 
demonstrated that caspase-8 is associated with Focal Adhesion Kinase (FAK) and CNB2 
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and upon its recruitment and association with these focal adhesion players, leads to the 
activation of the calpain family of proteases which then cleave Talin. As indicated by the 
authors the N-terminal cleavage product of Talin is termed the FERM, an integrin 
binding domain which facilitates cell migration (Barbero et al., 2009) and thus 
implicating that caspase-8 serves a role in mediating metastasis through its involvement 
with the focal adhesion complex (Barbero et al., 2009).  Subsequent evidence identified 
Rab5, as a critical modulator of caspase-8 action in cell migration (Torres et al., 2010; 
Torres et al., 2008). Rab5 itself plays several roles with migration, either through 
lamellipodia formation (Spaargaren and Bos, 1999), β1 integrin binding, or through actin 
cytoskeletal rearrangement (Pellinen and Ivaska, 2006; Pellinen et al., 2008). 
Several lines of evidence have demonstrated the involvement of caspase-8 in EGF 
signaling pathways inducing ERK activation through the incorporation of caspase-8 in 
SRC containing complexes.  This work identified through a RXDLL motif found within 
the DED of caspase-8 pro-domain, this allows caspase-8 to associate with SRC although 
the data did not show any evidence that caspase-8 phosphorylation was required for SRC 
association and EGF pathway activation (Finlay et al., 2009; Finlay and Vuori, 2007).  
Initiator caspase-8 is a critical player for extrinsic pathway activation, and because of its 
importance caspase-8 has been considered a tumor suppressor molecule. Caspase-8 
deficient cells are insensitive to death ligand stimulus and cannot induce apoptosis 
through the extrinsic pathway and this provides the cell an opportunity to undergo 
cellular tumorgenesis (Krelin et al., 2008).  Human cancer cells regulate caspase-8 
activity through a variety of mechanisms, one mechanism is caspase-8 partial or whole 
gene deletion, (Teitz et al., 2000) or gene methylation. For example, Medulloblastoma 
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Pediatric Neuroblastoma tumors down-regulate caspase-8 expression through 
methylation of the caspase-8 promoter thereby inhibiting caspase-8 transcription thus 
preventing protein translation and expression (Gonzalez-Gomez et al., 2004; 
Muhlethaler-Mottet et al., 2003; Pingoud-Meier et al., 2003).   
Several caspase-8 mutations have been identified in various tumor types. An 
interesting study by Soung et al, involved a screen across multiple cancer types to 
uncover common caspase-8 mutations among these cancer types (Soung et al., 2005).  
This screen identified frame shift and missense mutations which altered amino acid 
compositions in the DED domain, a domain which is absolutely critical for caspase-8 
recruitment to the DISC and initiating subsequence cleavage events (Soung et al., 2005).  
Moreover, mutations were found in the p18 catalytically active subunit and the p10 
regions validation of the screen results revealed that most of the mutants severely 
diminished apoptosis induction in gastric carcinomas (Soung et al., 2005).  
One unique feature of caspase-8 and caspase-10 is that these the only caspases 
processed at the DISC localized at the plasma membrane. Upon recruitment to the DISC 
caspase-8 undergoes two cleavage events, the first cleavage event occurs at aspartic acid 
residue 384 in the p10 subunit, giving rise to the p43/41 intermediate which is bound at 
the DISC.  This cleavage event is followed by a second cleavage at aspartic acid residues 
210, 216 which then release caspase-8 from the DISC into the cytosol (Fig. 1.3.3).   
Caspase-8 binding has been extensively studied throughout the years by several 
investigators, most notably; the pioneer work by Dr. Marcus Peter defined how the DISC 
components were assembled at the plasma membrane through TRAIL and/or FAS 
receptor and FADD palmitylation (Feig et al., 2007; Medema et al., 1997a; Medema et 
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al., 1997b).  Moreover studies by Walczak et al, and Lenardo et al, provided evidence 
towards DISC mediated caspase-8 processing (Ganten et al., 2004; Martin et al., 1998) 
Additional studies focusing on DISC formation by Marcus Peter’s lab identified that c-
flip was a specific inhibitor of caspase-8 DISC recruitment and activation  (Scaffidi et al., 
1999).  Subsequent work identified cFlip isoforms that block gene induction as well as 
processing of caspase-8 (Kavuri et al., 2011).  Aside from cFlip, investigators have 
shown that either XIAP or cIAP are also capable of blocking caspase-8 activation 
(Kruidering and Evan, 2000). 
More recent studies by Peng et al and Jin, et al(Jin et al., 2009; Peng et al., 2011), 
have shown that caspase-8 is polyubiquitinated in HEK293 cells under EGR activated 
conditions (Peng et al., 2011) or in lung cancer cell line H460 (Jin et al., 2009). 
Previously our lab has shown that proteasome inhibition and TRAIL can induce TRAIL 
mediated apoptosis in TRAIL resistant prostate cancer cell lines and through these studies 
we acquired data that further suggested caspase-8 was under proteasome regulation 
(Christian et al., 2009b; Thorpe et al., 2008b).  
 
1.6 Proteasome Regulation of Cellular Proteins. 
Protein degradation is an important process that affects a myriad of pathways. The 
proteasome has a role in regulating protein expression and in maintaining protein 
integrity (clearing misfolded proteins)(Davies, 2001; Leverkus et al., 2003). Protein 
degradation is mediated primarily through the ubiquitin proteasome system (David et al., 
2002), which involves the covalent attachment of ubiquitin to the lysine residues of the 
target protein or other ubiquitin residues (K48-G76 linkages) to result in the formation of 
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a ubiquitin chain (Shabek et al., 2009). The ubiquitination process is carried out by three 
key enzymes, the E1 ubiquitin activating enzyme, E2 conjugating enzyme, and E3 ligase 
which transfers the ubiquitin to the lysine residue of the protein (Soucy et al., 2009b). 
There are two classes of E3 ligases, the HECT class, which directly transfers ubiquitin 
from the E2 conjugating enzyme to the substrate, and RING finger class, which acts as a 
scaffold bringing the protein substrate in contact with ubiquitin containing E2 enzyme 
(Joazeiro and Weissman, 2000; Soucy et al., 2009a). Once polyubiquitinated, the protein 
is then translocated to the 26S proteasome, which in an ATP dependant manner, degrades 
the protein (Fig. 1.6.1). The 26S proteasome (Fig. 1.6.2) has a barrel like structure and is 
composed of 19S and 20S particles. The 19s is a regulatory particle and identifies 
ubiquitin bound proteins, and removes ubiquitin as the protein enters the catalytically 
active 20S particle. The 20S particle consists of two α and two β domains and contains 
several different proteases that degrade the protein (Orlowski and Wilk, 2000).  
 
1.7 Proteasome Inhibition. 
Investigators have shown that proteasome inhibitors can induce apoptosis and 
thus have been used as an anti-cancer strategy (Shah et al., 2001; Vu et al., 2008).  There 
are two types of proteasome inhibitors, natural inhibitors (lactacystin and epoxomicin) 
and synthetic inhibitors such as MG132 and Velcade (Almond and Cohen, 2002). MG132 
inhibits the chymotrypsin like activity of the 26S proteasome (Li et al., 2007b). Velcade, 
(PS-341/bortizomib) is an FDA approved proteasome inhibitor used in treating multiple 
myeloma (Crawford et al., 2006). Velcade is a dipeptide boronic acid small molecule that 
blocks the chymotrypsin-like activity of the 20S particle (Berkers et al., 2005). 
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Investigators have reported that Velcade has an impact on several key cellular processes 
such as, inhibiting cell cycle and NF-κB activation (Yu et al., 2004). Velcade has been 
shown to sensitize cancer cells to apoptosis through several mechanisms, such as the 
down-regulation of c-Flip, which inhibits caspase-8 activation at the DISC (Fukazawa et 
al., 2001; Sayers et al., 2003). Several in vitro and in vivo studies have shown that 
Velcade is successful in inducing apoptosis in multiple myeloma cells (Balsas et al., 
2009). 
 Although Velcade is effective against multiple myeloma and evidence is growing 
supporting Velcade as an effective anti-cancer strategy in other cancer cell lines, Velcade 
has drawbacks, such as cell resistance and lack of specificity. Some studies have shown 
that multiple myeloma patients were either initially resistant or acquired resistance to 
Velcade during the course of treatment with this drug (Nencioni et al., 2005). Attempts to 
overcome Velcade resistance have led to development of various combinations of 
Velcade with different chemotherapeutic agents such as, PCI-24781 (an HDAC inhibitor) 
which was found to synergize with Velcade to induce reactive oxygen species damage as 
well as caspase-8 activation in Non-Hodgkins lymphoma (Bhalla et al., 2009).  
Significantly enough, Mitsiades and colleagus (Mitsiades et al., 2003), showed 
that Velcade in combination with Doxorubicin, can effectively overcome Velcade 
resistance in multiple myeloma. Another anti-cancer strategy involved using Velcade in 
combination TNF-α Related Apoptosis Inducing Ligand (TRAIL). Recent studies by 
Christian et al suggests the ability of Velcade to sensitize TRAIL resistant prostate cancer 
cell lines in vitro and in vivo to TRAIL mediated apoptosis and together TRAIL and 
Velcade stabilize caspase-8 p18 subunit (Christian et al., 2009a; Thorpe et al., 2008a).  
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A major caveat for using Velcade as an anti-cancer strategy is the lack of cell type 
and cell signaling specificity. Velcade was designed to block the proteasome and not to 
discriminate between a malignant or a healthy cell therefore, all cells are impacted by 
Velcade treatment. Additionally, although Velcade specifically targets the proteasome 
evidence shows that multiple pathways are impacted and as a result of the non-specific 
pathway modulation, Velcade treatment can lead to side effects such as 
thrombocytopenia and peripheral neuropathy (Badros et al., 2007; Richardson et al., 
2009).  To bypass the caveats associated with Velcade, while achieving apoptosis 
induction investigators have taken an interest in studying the activity of E3 ligases in an 
attempt to achieve and their potential involvement with the extrinsic pathway of 
apoptosis.  
Emerging evidence provided by two different groups, Jin et al, (2009) and Peng et 
al, (2011), provided new insights regarding caspase-8 polyubiquitination.  Jin et al, 
provided evidence that showed E3 ligase CUL3 mediated polyubiquitination lead to 
caspase-8 incorporation into an aggresome. Moreover functional activity analysis 
established that caspase-8 was catalytically active within the aggresome. The authors 
concluded CUL3 mediated polyubiquitination of caspase-8 promotes p62 mediated 
aggresome formation and that both events play a role in caspase-8 activation. Although 
caspase-8 ubiquitination may initially result in enzymatic activation, Jin et al only studied 
very early time points. Our data suggests that caspase-8 ubiquitination ultimately results 
in its degradation by the 26S proteasome (p18 subunit) and, thereby, would limit caspase-
8 activity and block apoptosis. A second group investigated caspase-8 polyubiquitination 
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while studying EGR signaling, more specifically looking at the phosphorylation of 
caspase-8 through Thr 263 mediated through RSK6 activity (Peng et al., 2011).  
Studies from our lab also discovered two E3 ligases, Siah2 and POSH that play a 
role in modulating caspase-8 activity (Christian et al., 2011).  These E3 ligases were 
discovered using a siRNA screen from Dharmacon which knocked down roughly 230 of 
the known E3 ligases at that time.  By reverse transfecting DU145 prostate cancer cells 
and assessing caspase-8 activity following TRAIL and proteasome inhibitor stimulation, 
the data revealed that knocking down Siah2 and POSH led to dramatic increases in 
caspase-8 activity.  Furthermore Siah2 and POSH can functionally regulate caspase-8 
activity down-stream of the DISC and caspase-8 processing(Christian et al., 2011).  
Combination treatment of proteasome inhibition with TNF-α related apoptosis 
inducing ligand (TRAIL), induces apoptosis in TRAIL resistant prostate cancer cells in-
vitro and in-vivo(Christian et al., 2009b).  Moreover combination of TRAIL and Velcade 
led to caspase-8 p18 subunit stabilization(Brooks et al., 2010; Thorpe et al., 2008b), 
evidence implicating caspase-8 degradation under the control of the 26S proteasome (Fig. 
1.6.1).  This study was designed to determine the functional consequences of proteasome 
inhibition on caspase-8 trafficking, ubiquitination, and activity in cancer cells.   
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Figure 1.1.1 Mechanisms of Cancer  
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Figure 1.1.1 Mechanisms of Cancer.   
As cells undergo tumorgenesis critical regulatory mechanisms are inhibited. Through 
inhibition of these mechanisms cell proliferation becomes unregulated, cells are capable 
of autocrine/paracrine stimulation of growth pathways.  Increased proliferation leads to 
increased DNA replication resulting in accumulation of mutations that causes genomic 
instability.  Genome mutations ultimately lead to acquisition of new characteristics such 
as tissue/organ invasion and angiogenesis. Apoptotic pathways are down-regulated.  
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Figure 1.1.2 The Actions of p53 in Cell Cycle Arrest 
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Figure 1.1.2 The Actions of p53 in Cell Cycle Arrest.  
Cell cycle activation involves a series of checkpoints through interphase which are 
governed by the interplay between CDK and cyclin families of proteins and the 
regulatory molecules that modulate their expression.  A critical regulatory molecule is 
p53 which assesses DNA integrity prior to entry into S phase.  Should DNA integrity be 
irreparable  p5 will signal a series of signaling pathways that inhibit cell cycle, induce 
apoptosis, and block survival pathways.  MDM2 facilitates the polyubiquitination of p53 
leading to its degradation.  
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Figure 1.1.3 AKT Pathway 
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Figure 1.1.3 AKT Pathway. 
 Mediated through a variety of cell signaling events within the cell.  Once activated, PI3K 
phosphorylates PIP2 thus generating PIP3 which can then activate PIDK, leading to AKT 
activation.  
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Figure 1.3.1. Anoikis Pathway.  
 
  
34 
 
Figure 1.3.1. Anoikis Pathway.  
Integrin and extracellular matrix protein signaling is interrupted, the cell detaches from 
the CM, this leads to signals throughout the cell to induce in intrinsic pathway of 
apoptosis  
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Figure 1.3.2 Intrinsic and ER Pathways of Apoptosis.  
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Figure 1.3.2 Intrinsic and ER Pathways of Apoptosis. 
 The intrinsic pathway of apoptosis is activated through a variety of signals.  This leads to 
a down-regulation of anti-apoptotic BCL family members, allowing pro-apoptotic 
members to perturb the mitochondria.  Cytochrome C release from the mitochondria 
leads to APAF-1 and pro-caspase-9 recruitment forming the Apoptosome. Upon 
formation caspase-9 is processed and cleaves downstream targets, such as executioner 
caspases 3, 7. The ER stress pathway induces the activation of caspases 2, or 4, leading to 
12 activation which then activations the intrinsic pathway of apoptosis.  
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Figure 1.3.3. TRAIL Mediated Extrinsic Pathway of Apoptosis .  
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Figure 1.3.3. TRAIL Mediated Extrinsic Pathway of Apoptosis . 
 Mediated through the binding of TRAIL to its cognate receptor, upon binding the 
receptors oligomerize within the membrane. Fas associated Death Domain (FADD) is 
recruited, followed by pro-caspase-8 which is then processed into its active p18 and p10 
subunits which then can oligomerize into a heterotetramer 
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Figure 1.3.4. TNF-α Mediated NFκB or Apoptosis Activation.   
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Figure 1.3.4. TNF-α Mediated 
 NFκB or apoptosis activation.  TNF-alpha activation can elicit its signaling events 
through the formation of two complexes. Complex 1 mediates the NFκB activation 
through the K3 ubiquitin linkage of RIP1. This leads IKK activation via TAK1/TAB2/3, 
IKK then goes on to phosphorylates IkB, causing its polyubiquitination and degradation, 
thus releasing NFκB to translocate to the nucleus.  
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Figure 1.3.5  Ripoptosome Formation.  
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Figure 1.3.5  Ripoptosome Formation. 
A 2mD complex discovered to form independent of receptor or mitochondrial activation.  
The ripoptosome forms upon depletion of cIAP either through etoposide, SMAC over-
expression or through SMAC mimetics. The major components are phosphorylated RIP1, 
FADD and caspase-8.  This complex has been shown to induce apoptosis through 
caspase-8 processing. 
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Figure 1.4.1. General Cleavage Events for Critical Apoptotic Related Caspases. 
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Figure 1.4.1. General Cleavage Events for Critical Apoptotic Related Caspases. 
Caspases 8 and 10 are larger than other caspases because they contain DED domains 
responsible for binding to the DISC complex. 
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Figure 1.4.2 Unfolded Protein Response and Intrinsic Pathway Activation. 
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Figure 1.4.2 Unfolded Protein Response and Intrinsic Pathway Activation.  
Sensor proteins IRE-1 ATF-6, and PERK detect an overload of misfolded or unfolded 
proteins and up-regulate protein folding chaperones and machinery to clear ER load. 
Extended periods of ER stress results in the up-regulation of CHOP which inhibits the 
anti-apoptotic BCL family members allowing BAD/BAX to induce the intrinsic pathway 
of apoptosis induction.  
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Figure 1.6.1.  Ubiquitin Proteasome System.  
 
 
 
‘ 
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 Figure 1.6.1.  Ubiquitin Proteasome System.  
Pathway involved with mediating the co-valent attachment of ubiquitin to proteins 
marked for degradation.  Ubiquitin tagging is mediated through three classes of enzymes 
E1 (ubiquitin activating) E2 (ubiquitin conjugated) and E3 (Ubiquitin Ligase). E3 ligases 
facilitate the transfer of ubiquitin to the target substrate.  
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Figure 1.6.2. The 26S Proteasome.  
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Figure 1.6.2. 26S Proteasome: Composed of 19s regulatory subunit that recognizes 
polyubiquitinated proteins and recycles Ubiquitin and the 20s particle which contains the 
catalytic activity of the proteasome.  
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Figure 1.7.1.Proteasome Inhibition Stabilizes Caspase-8 p18 Catalytically Active Subunit 
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Figure 1.7.1. Proteasome Inhibition Stabilizes Caspase-8 p18 Catalytically Active 
Subunit 
We hypothesized that caspase-8 was degraded by the 26S proteasome. Proteasome 
inhibition can stabilize the catalytically active caspase-8 p18 subunit by preventing its 
degradation by the 26S proteasome. 
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             Chapter 2: Materials and Methods 
               
2.1. Cell Culture and Reagents 
Human prostate cancer lines, LNCaP and PC3 were cultured in Dulbecco’s 
Modified Eagles Media (DMEM) (Media Tech Inc, Manassas, VA), or F12K media 
(Media Tech Inc, Manassas, VA). Lung cancer cell line H460 (a kind gift from Dr. John 
Yanneli at University of Kentucky, Lexington KY), Jurkat T cell line was purchased 
from the American Type Culture Collection (ATCC) and Neuroblastoma cell line (NB7) 
caspase-8 deficient cell line  (Caspase-8 constructs and NB7 cell line were a very 
generous gift from Drs. Andrew Oberst and Doug Green (St. Jude Children’s Research 
Hospital, Memphis, TN) were cultured in RPMI (Mediatech). Media was supplemented 
with 10% FBS (Cellagro), 1% Penicillin (10,000 I.U/ml) / Streptomicin (10,000ug/ml). 
Epoxomicin was a generous gift provided by Dr. Kyung Bo Kim (College of Pharmacy, 
University of Kentucky). Velcade (Millennium Pharmaceuticals, Cambridge, MA) was 
donated by the University of Kentucky, Markey Cancer Center Pharmacy.  The GST-
TRAIL fusion protein as purified using affinity chromatography as described (Christian 
et al., 2009b; Thorpe et al., 2008b).  Caspase-8 reconstitution was carried out as 
described in (Oberst et al., 2010). NB7 cells were transduced with RT virus encoding 
either wild-type or non-cleavable mutant caspase-8 constructs (Caspase-8 expression was 
standardized via flow cytometry (Beckman Coulter MoFlo, Ft.Collins, CO) at Flow 
Cytometry Core Facility, University of Kentucky.  
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2.2 Cell Viability and Apoptosis Evaluation 
Cell viability was assessed using MTT, (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide)), after treatment with GST-TRAIL or Epoxomicin. Results 
were read using a spectrophotometer at 570 nm minus 690 nm.  For evaluation of 
apoptosis induction we employed Annexin V, APC/PI (Invitrogen, Eugene, OR) staining.  
Cells were seeded in 24-well plates and treated with GST-TRAIL or Epoxomicin 
separately or in combination. After treatment, cells were harvested, washed with Annexin 
V binding buffer, resuspended in Annexin binding buffer with PI, and Annexin V APC 
was added to samples as recommended by manufacturer. Staining was analyzed by flow 
cytometry (FACSCalibur, BD Immunocytometry Systems, San Jose, CA) at the Flow 
Cytometry Core Facility, University of Kentucky. Annexin V positive and viable cells 
were quantified using CellQuest Pro software (BD Immunocytometry Systems, San Jose, 
CA) in 20,000 gated events.   All MTT and Annexin V/PI experiments were performed in 
triplicate.  
 
2.3. Half-life Evaluation  
 Cells (2x10
6
) were plated into 6 well plates, were either pre-treated with 
proteasome inhibitor or not, followed by 100ng GST-TRAIL stimulation for two hrs. 
After two hrs cells were treated with cycloheximide or caspase inhibitor Z-VAD-FMK 
and harvested at indicated time points.  Caspase-8 expression was analyzed using 
Western blot with the monoclonal IC12 caspase-8 antibody (Cell-Signal Technology, 
Danvers, MA). 
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2.4. Polyubiquitin Immunoprecipitation (IP) and Western Blot Analysis 
LNCaP cells (6x10
6
) were treated either separately or in combination with GST-
TRAIL (400ng/ml) or (1μM) Epoxomicin for 8hrs. Cells were subsequently harvested in 
(1%) NP-40 in PBS and protein content was determined using BCA assay (Pierce). Prior 
to immunoprecipitation, lysates (10% of total lysate) were used as input. Polyubiquitin 
immunoprecipitation was performed using Ubiquitin Enrichment Kit (Thermo Fisher 
Scientific, Rockford, IL) and caspase-8 expression was determined using Western blot 
probing with the monoclonal IC12 anti-caspase-8 antibody (Cell Signaling Technology, 
Danvers, MA). 
 
2.5. Subcellular Fractionation  
LNCaP (1.2x10
7
) or NB7 (1.6 x 10
7
) cells were plated into 100mm tissue culture 
plates and were treated with GST-TRAIL (400ng/ml) and/or (1μM) Epoxomicin. All 
steps were performed at 4
o
C. After treatment cells were harvested in 1x sucrose buffer A, 
subjected to dounce homogenization and centrifugation (1000xg; 10mins). Lysates were 
overlayed onto a 30% Percoll gradient in 2x buffer A and subjected to ultracentrifugation 
in a Beckman Coulter Optima L-90K Ultracentrifuge (1hr, 26,000 RPM (61,000 x g) at 
4
o
C). Following ultracentrifugation, cytosol and plasma membrane fractions were 
collected; inner membrane fractions were collected by adding 1x buffer to 30% Percoll 
(GE Healthcare)/2x sucrose buffer A followed by ultracentrifugation (1hr, 200,000xg at 
4
o
C).  Cellular fractions were subjected to Western blot analysis and/or caspase activity 
assays.  
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2.6. Caspase-8 Activity Evaluation 
NB7 cells (1.6x10
7
), parental or caspase-8 expressing clones were treated either 
separately or in combination with GST-TRAIL (100ng/ml) or (1μM) Epoxomicin for 
4hrs, caspase-8 activity was assessed using the Caspase-8-glo luminescence kit,  
(Promega, Madison, Wisconsin) according to the manufacturer’s protocol; luminescence 
was measured by using Veritas™ Microplate luminometer (Promega Corp., Sunnyvale, 
CA). NB7 cells were subjected to caspase-8 immunoprecipitation either in whole cell 
lysate or cytosol and plasma membranes fractions. Caspase-8 activity assay was 
performed on the beads containing antibody-caspase-8 complexes.  All experiments were 
performed in triplicate.  
 
2.7. Immunocytochemical Analysis   
EZslide (Millipore, Temecula, CA) were coated with 400ng Fibronectin (Sigma, 
St. Louis, MO) for 2hrs. LNCaP cells (8x10
4
) were plated into each well and treated with 
100ng GST-TRAIL or 1uM Epoxomicin separately or in combination. Cells were fixed 
with 4% paraformaldehyde, permiabilized with SAP buffer, blocked with BSA and 
probed with respective primary antibodies, (Affinity purified polyclonal caspase-8 (R&D, 
Minneapolis, MN), and Na
+
K
+
 ATPase (Millipore Temecula CA) and 26S Proteasome 
20S particle (Calbiochem, San Diego, CA).  Cells were washed with 1X PBST and 
probed with either 488 Alexa fluor goat-anti-mouse or 594 Alexa Fluor goat-anti rabbit, 
(Invitrogen, Eugene, OR) conjugated secondary antibodies.  Following secondary 
antibody incubation and wash steps, slides were mounted using Vectashield (Vector 
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laboratories Inc, Burlingame, CA).  Images were photographed using Leica TSP SP5 
Confocal microscope at University of Kentucky Imaging Facility.  
 
2.8. Statistical Analysis 
MTT and Annexin V/PI experiments were performed in triplicate and data were 
standardized to the non-treated results.  Caspase-8 activity assay results acquired from 
either whole cell lysates or fractions were normalized to protein concentrations based on 
BCA protein quantification. Half-life Western blots were quantified by densitometry 
using the Image J software.  All experiments were performed in triplicate and the data  
were analyzed using unpaired Student t-Test analysis. Statistical significance of values 
among different treatment groups was set at p < 0.01 
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                              Chapter 3 Experimetnal Outcomes 
                           
3.1a. Caspase-8 Activation is Independent of Caspase-8 Processing   
We previously demonstrated that the combination of TRAIL and proteasome 
inhibitor not only restored TRAIL sensitivity in TRAIL resistant prostate cancer 
(LNCaP) in both in-vitro and in-vivo models (Christian et al., 2009b) but also leads to 
stabilization of caspase-8 p18 subunit (Thorpe et al., 2008b).  Our goal was to further 
examine the impact of proteasome inhibition on caspase-8 using non-cleavable caspase-8 
constructs (Fig. 3.1.1a, Panel A). After successful reconstitution of wild-type and non-
cleavable caspase-8 mutant constructs in NB7 caspase-8 deficient cells (Fig. 3.1.1a, panel 
B), caspase-8 activity was comparatively analyzed between the wild-type and non-
cleavable constructs in response to treatment. Caspase-8 activity was analyzed in either 
whole cell lysates or cytosolic and plasma membrane fractions (Fig. 3.1.1a, panels C and 
D respectively) subjected to caspase-8 immunoprecipitation. Low levels of caspase-8 
activity were observed in cells treated with GST-TRAIL alone and activity increased 
when epoxomicin was used with TRAIL in combination. The caspase-8 non-cleavable 
mutants possess higher levels activity than the wild-type caspase-8 (Fig. 3.1.1a panel C) 
(P = 0.017, 0.031, 0.003). This prompted us to analyze Analysis of caspase-8 activity in 
the subcellular fractions; the results indicate that the wild-type caspase-8 had the highest 
level of activity in the cytosol and the lowest at the membrane, while the non-cleavable 
constructs had significantly low activity in the cytosol and higher at the plasma 
membrane (Fig. 3.1.1a, panel D).  
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3.1b. Caspase-8 Processing not Required for Apoptosis Induction.  
We subsequently compared cell viability and apoptosis induction between the 
wild-type and non-cleavable caspase-8 constructs. Treatment with either GST-TRAIL or 
Epoxomicin separately or in combination, led to significant decrease in cell viability in 
NB7 caspase-8 expressing cell lines (Fig. 3.1.1b, panel A).  Treatment with a lower dose 
of GST-TRAIL revealed that the non-cleavable mutants were more effective at inducing 
apoptosis than wild-type caspase-8 (Fig. 3.1.1b, panel B).  The combination of GST-
TRAIL and Epoxomicin resulted in a significant induction of apoptosis (Fig. 3.1.1, panel 
C, P = 0.0001, 0.0001, 0.0001).  
 
3.2a. Proteasome Inhibition Stabilizes Caspase-8 p18 Subunit.  
Proteasome inhibition confers caspase-8 stabilization in different cancer cell lines; 
PC3 (prostate cancer), Jurkat (T cell), and H460 (lung cancer) cell lines (Fig. 3.2.1a, 
panels A, B, C).  Either simultaneous addition of GST-TRAIL and proteasome inhibitor 
or proteasome inhibitor pretreatment followed by GST-TRAIL stimulation leads to 
caspase-8 p18 subunit accumulation (Fig 3.2.1a, panels A, B, C).  To determine whether 
accumulation of the caspase-8 p18 subunit is a result of proteasome inhibition (and not 
due to increased processing), we evaluated the half-life of p18 and p10 subunits in the 
presence and/or absence of proteasome inhibitor.  Proteasome inhibition stabilizes 
caspase-8 p18 subunit, thereby extending its half-life (Fig. 3.2.1, panels D and E). Thus 
p10 expression persisted over time in the presence or absence of proteasome inhibitor 
(Fig. 3.2.1, panel F). 
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3.2b. Processed Caspase-8 is Polyubiquitinated. 
The next sequence of experiments set to determine whether pro-caspase-8 or 
cleaved caspase-8 was polyubiquitinated.  We used the LNCaP human prostate cancer 
cell line and performed caspase-8 immunoprecipitation followed by Western blot to 
probe for ubiquitin. LNCaP cells were treated with different combinations of proteasome 
inhibitors (Velcade or Epoxomicin) separately or in combination with GST-TRAIL. Input 
was analyzed by Western blotting and caspase-8 IP followed by Western blot analysis 
probing for polyubiquitin (Figure 3.2.1b, panels A and B, respectively). We observed 
polyubiquitin smears in the GST-TRAIL and GST-TRAIL/Velcade treated lanes and no 
trace of polyubiquitin in the non-treated or Velcade only lanes.  These results were 
further supported by immunoprecipitation (IP) analysis using the Ubiquitin Enrichment 
kit to pull-down ubiquitinated proteins and Western blotting for caspase-8 (Fig. 3.2.1b, 
panel D). Probing for the caspase-8 p10 subunit, revealed that the p10 is not 
polyubiquitinated (data not shown). 
 
3.3a. Proteasome Inhibition Increases Caspase-8 Accumulation in the Cytosol and 
Plasma Membrane.   
To determine the impact of proteasome inhibition on caspase-8 trafficking, I 
employed subcellular fractionation which yielded cytosol, plasma membrane, and 
internal membrane fractions. To assess if proteasome inhibition modulated caspase-8 
trafficking, LNCaP cells were treated with Epoxomicin and GST-TRAIL separately or in 
combination followed by subcellular fractionation and caspase-8 expression was 
analyzed via Western blot (Fig. 3.3.1a, panel A). Caspase-8 expression was not detected 
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in the internal membrane fractions however, there was caspase-8 expression (full-length 
and cleaved forms) in cytosol and plasma membrane fractions (Fig. 3.3.1a, panel B). The 
p43/41 intermediate and p18 subunit expression was predominantly elevated in the 
plasma membrane than cytosol. This accumulation of the p43/41 intermediate and p18 
subunit in the plasma membrane and cytosol fractions was enhanced in the presence of 
the proteasome inhibitor (Fig. 3.3.1a, panel B).   
 Next I pursued to examine the consequences of caspase-8 activity in LNCaP cells. 
As shown in Figure 3.3.1a caspase-8 p43/41 expression with epoxomicin and GST-
TRAIL treatment was higher than when cancer cells were exposed to GST-TRAIL alone 
(Fig. 3.3.1a, panel C).  There was however an increase in plasma membrane associated 
caspase-8 activity with GST-TRAIL treatment alone and a marked increase in caspase-8 
activity with the combination of GST-TRAIL and epoxomicin (Fig. 5, panel C)(P = 0.001 
and P = 0.0006). Time course analysis of the consequences of proteasome inhibition on 
caspase-8 trafficking and activity in LNCaP prostate cancer cells, revealed that p43/41 
intermediate expression increased in the plasma membrane (Fig. 3.3.1a, panel D).  There 
was a temporal increase in the activity in both fractions followed by a steep decline 
observed in the plasma membrane fraction (Fig. 3.3.1, panel E) ( 2hr fractions P = 
0.0001, 4hr fractions, cytosol P = 0.0003, pm P = 0.0001, 6hr fractions P = 0.0001, 8hr 
fractions  P = 0.0001, 12hr = 0.0001).   
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3.3b. Caspase-8 Co-localizes with Na
+
/K
+
 ATPase.  
To confirm the fractionation data immunocytochemistry analysis was conducted, I 
used confocal microscopy to determine whether caspase-8 co-localizes with Na
+
/K
+
 
ATPase (Fig. 3.3.1b).  LNCaP cells were treated and subjected to fluorescence staining as 
described above, to determine the cellular localization of the 20S particle of the 26S 
proteasome and Na
+
/K
+
 ATPase.  The representative images shown on figure 3.3.6 
clearly indicate the lack of  co-localization between the 26S proteasome and the Na
+
/K
+
 
ATPase, while there is significant co-localization detected between caspase-8 and Na
+
/K
+
 
ATPase, in untreated and treated prostate cancer cells. 
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Figure 3.3.1a: Caspase-8 Processing is not Required for Activation of Apoptosis.   
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Figure 3.3.1a: Caspase-8 processing is not required for activation or apoptosis.  A) 
Schematic showing caspase-8 non-cleavable mutant constructs. B). Western blots 
demonstrating successful reconstitution and respective cleavage events of wild-type and 
mutant caspase-8 in NB7 cells. C) MTT viability studies NB7 cells treated with a 
combination of epoxomicin and GST-TRAIL (50ng or 100ng as indicated) following 
treatment MTT was performed. D) Apoptosis induction was measured in NB7 cells that 
were treated as indicated and stained with Annexin V/ PI followed by analysis by FACS 
analysis. Figure E) Caspase-8 activity was evaluated in NB7 cell lines treated as indicated 
for 4 hours. Whole lysates were subjected to IP and activity was measured using the 
caspase-8 containing beads.  F) Caspase-8 activity was measured in cytosol and plasma 
membrane factions using the same treatment conditions described in E), followed by 
subcellular fractionation and evaluating caspase-8 activity as described in materials and 
methods (F).  
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Figure 3.1.1b. MTT Viability and Annexin V/PI Studies  
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Figure 3.1.1b. MTT Viability and Annexin V/PI Studies.  
NB7 cells treated with a combination of epoxomicin and GST-TRAIL [50ng (7.5 hrs) or 
100ng (5.5 hrs) as indicated] following treatment MTT was performed (A, B). Apoptosis 
induction was measured in NB7 cells that were treated as indicated and stained with 
Annexin V/ PI followed by analysis by FACS analysis (C). 
  
67 
 
Figure 3.2.1a Proteasome Inhibition Stabilizes Caspase-8 p18 Subunit and Extends 
the Half-life. 
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Figure 3.2.1a Proteasome Inhibition Stabilizes Caspase-8 p18 Subunit and Extends 
the Half-life. 
Panels A, B and C; PC-3, Jurkat, H460 cells were plated into 6-well dishes, treated with 
proteasome inhibitor and GST-TRAIL. Treated and untreated control cells were 
harvested and caspase-8 expression was analyzed by Western blot. Proteasome inhibition 
leads to caspase-8 stabilization.  Panels D, E; caspase-8 p18 subunit half-life studied. 
Panel F; Quantification of p18 half-life data on panel E.  
  
69 
 
Figure 3.2.1b: Processed Caspase-8 is Polyubiquitinated.    
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Figure 3.2.1b: Processed Caspase-8 is Polyubiquitinated.  
Polyubiquitin immunoprecipitation was carried out using the protocol for Ubiquitin 
Enrichment kit. LNCaP cells were treated with GST-TRAIL or Epoxomicin separately or 
in combination for 8 hrs. A). Western blot analysis of caspase-8 expression in response to 
Epoxomicin and GST-TRAIL treatments prior to Ubiquitin pull down.  Panel B, Western 
blot showing caspase-8 polyubiquitination following Ubiquitin IP.  
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Figure 3.3.1a:  Proteasome inhibition leads to increased cleaved caspase-8 in plasma 
membrane.  
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Figure 3.3.1a:  Proteasome Inhibition Leads to Increased Cleaved Caspase-8 in 
Plasma Membrane. 
 Panel A, Markers indicating integrity of fractions. B. Western blot showing caspase-8 
expression only in cytosol and plasma membrane fractions. C. Western blot showing 
impact of proteasome inhibition on caspase-8 expression in cytosol and plasma 
membrane fractions.  
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Figure 3.3.1b: Co-localization of caspase-8 with Na
+
K
+
 ATPase. 
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Figure 3.3.1a:  Proteasome Inhibition Leads to Increased Cleaved Caspase-8 in 
Plasma Membrane. Panel A, Markers indicating integrity of fractions. B. Western blot 
showing caspase-8 expression only in cytosol and plasma membrane fractions. C. 
Western blot showing impact of proteasome inhibition on caspase-8 expression in cytosol 
and plasma membrane fractions.  
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                                         Chapter 4 Discussion 
   
Growing evidence supports a dynamic functional interaction between proteasome 
inhibition and caspase-8 mediated apoptosis in cancer cells from different cell types 
(Brooks et al., 2010; Jane et al., 2011; Koschny et al., 2007).  The combination of TRAIL 
and Velcade has become a promising chemotherapeutic strategy because of their efficacy 
of inducing apoptosis in tumors (Christian et al., 2009b; Mitsiades et al., 2001; Sayers et 
al., 2003). Another advantage to using TRAIL as a chemotherapeutic agent is its 
specificity in inducing apoptosis in tumor cells and not healthy cells (Plasilova et al., 
2002; Zhang et al., 2010).  The present study establishes that proteasome inhibition 
increases cleaved caspase-8 stability as well as caspase-8 activity and protein 
accumulation at the plasma membrane and in the cytosol.  Using appropriate markers we 
verified our fractions and further interrogation revealed caspase-8 p43/41 and p18 
cleavage products in both the cytosolic and plasma membrane fractions, with p43/41 and 
p18 subunit expression were predominately in the plasma membrane.  
One may argue that it is still unclear on whether polyubiquitination occurs at the 
DISC causing its release into the cytosol or if polyubiquitination occurs in the cytosol 
following caspase-8 release from the DISC. It would indeed be of major significance to 
address this point and determine if caspase-8 is polyubiquitinated at the DISC or in the 
cytosol would provide a platform for further studying caspase-8 regulation. Identifying 
whether polyubiquitination is the trigger for releasing caspase-8 into the cytosol as well 
as identifying the specific E3 ligase responsible for caspase-8 K48 linked 
polyubiquitination. Evidence suggests that caspase-8 polyubiquitination can be either 
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K63 linked on the p10 subunit which leads to caspase-8 activation or K48 linkage leading 
towards caspase-8 degradation (Jin et al., 2009; Peng et al., 2011). Our results indicate 
that processed caspase-8 is polyubiquitinated on the p18 subunit rather than the p10 
subunit as previously shown (Jin et al., 2009). This evidence that supports p18 
polyubiquitination, is in the fact that the IC12 caspase-8 antibody targets an epitope in the 
p18 region. Therefore any caspase-8 polyubiquitination observed with this antibody 
implies that the p18 also a target site for polyubiquitination in addition to the p10 subunit 
as suggested by Jin et al (Jin et al., 2009). A key consideration is that we are investigating 
endogenous caspase-8 in a physiologically relevant tumor microenvironment, rather than 
non-cleavable constructs or caspase-8 fragments that may be characterized as artifacts. 
Indeed we focused on caspase-8 polyubiquitination under the activation of the extrinsic 
pathway of apoptosis, rather than through activation of non-apoptotic pathways, such as 
EGF signaling pathway (Peng et al., 2011). It could be argued that the conditions 
involved analyzing caspase-8 ubiquitination following EGF treatment are distinct from 
those due to death receptor activation.  The cellular platform hosting the kinetics for 
caspase-8 processing, polyubiquitination, and 26S proteasome degradation is cell type-
dependent and another compounding factor is that the entire pool of pro-caspase-8 is not 
completely processed into cleavage products. 
 To address these issues we performed a combination time-course and dose 
response experiments to determine the conditions that yielded the maximal amount of 
caspase-8 p18 product available for polyubiquitination. Velcade or Epoxomicin treatment 
revealed that caspase-8 polyubiquitination wasn’t the consequence of the actions of one 
specific inhibitor, but rather a specific result from proteasome inhibition. Epoxomicin 
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serves as a control indicates that caspase-8 p18 stabilization is a result of proteasome 
inhibition rather than through the potential manipulation of c-FLIP expression using 
Velcade or MG132 treatment (Li et al., 2007a; Liu et al., 2007). Ongoing studies seek to 
determine the cellular localization hosting the occurrence of caspase-8 
polyubiquitination, cytosol vs. plasma membrane.  
To further explore the mechanism of caspase-8 regulation, we used non-cleavable 
forms of caspase-8 and examined whether caspase-8 processing is required for caspase-8 
activation and apoptosis induction. We unexpectedly observed a decrease in cell viability 
with the D2A non-cleavable construct which was comparable to the D3A and wild-type 
caspase-8 constructs. Lower doses of GST-TRAIL (in combination with Epoxomicin), 
revealed that the D2A and D3A non-cleavable mutants had larger decreases in cell 
viability compared to wild-type caspase-8.  Annexin V/Pi staining complemented our 
MTT data as apoptosis induction was only observed upon combination treatment with 
Epoxomicin and GST-TRAIL. One may argue that the non-cleavable mutant forms of 
caspase-8 may be more effective in apoptosis induction due to caspase-8 forms being 
highly resistant to proteasome regulation.   
The present results establish that non-cleavable mutants D3A and D2A were 
capable of becoming activated in the presence of GST-TRAIL alone and the activity of 
these caspase-8 mutants were markedly increased with the combination of GST-TRAIL 
and Epoxomicin. Interestingly enough, the data revealed two activity patterns, in the 
cytosol caspase-8 activity decreased depending on the cleavage mutation; while in the 
plasma membrane the wild-type caspase-8 had the least amount of activity while the non-
cleavable D2A and D3A had higher activity. These findings in combination with the 
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LNCaP suggest that caspase-8 is processed at the DISC and is cycled back into the 
cytosol.  These data are interesting in their own right because the accepted dogma for 
caspase-8 activation and apoptosis induction (Martin et al., 1998; Medema et al., 1997a; 
Oberst et al., 2010) states that caspase-8 processing is required for activation and 
apoptosis induction; however, the D2A mutant is fully capable of doing both and this 
form of caspase-8 is not cleaved. This mechanistic insight challenges the existing 
caspase-8 dogma. Future studies will focus on examining the impact of proteasome 
inhibition on apoptosis induction with the D2A non-cleavable mutant.  Proteasome 
inhibition may potentially act to facilitate caspase-8 dimerization or stabilizes the p43/41 
intermediate form at the DISC.  Further elucidation of caspase-8 regulation could lead to 
the development of agents that stabilize the DISC with either full-length caspase-8 or 
p43/41 intermediate.  Stabilizing either form at the DISC would slow down or prevent 
rapid caspase-8 degradation and increase caspase-8 activity for apoptosis induction. Thus 
caspase-8 stabilizing agents would be highly selective for apoptosis induction in cancer 
cells. Such agents will potentially circumvent issues associated with conventional 
chemotherapy i.e. normal vs. cancer cell type-specificity, and natural or acquired 
resistance in cancer cells as associated with existing chemotherapeutics such as 
Doxorubicin or Velcade.  
  Taken together this evidence provides a strong platform for exploiting new 
potential molecular targets such as, E3 ligases responsible for caspase-8 degradation.  
Studies by Jin et al, provided evidence identifying CUL3 as an E3 ligase that modulates 
caspase-8 activation (Jin et al., 2009), and this is in accord with our previous studies 
indicating that E3 ligases Siah2 and furthermore, our previous studies revealed E3 
79 
 
ligases, Siah2 and POSH (Christian et al., 2011) have a role in modulating caspase-8 
activity. It is important to point out that in the Jin et al, studies caspase-8 degradation was 
not investigated and while our study provided the first evidence which showed SIAH2 or 
POSH had no impact caspase-8 processing or stability.   
Together, these studies suggest there is another E3 ligase capable of mediating 
caspase-8 polyubiquitination and degradation. Identifying this E3 ligase may reveal the 
trigger for caspase-8 release from the DISC, such as polyubiquitination which may occur 
following initial cleavage event at aspartic acid residue 384. This could also imply that 
perhaps there is a preferred cleavage intermediate (likely the p43/41) that is optimal for 
crossing the caspase-8 activity threshold required to induce apoptosis rather than 
complete processing of caspase-8 into the p18/10 heterodimer.  
Elucidating the mechanisms behind caspase-8 regulation can contribute to the 
generation of new effective caspase-8 driven anti-cancer approaches that activate or 
restore apoptosis in chemotherapeutic resistant cancer.  By identifying molecules critical 
for caspase-8 regulation, this could lead to the development of specific inhibitors 
designed to, stabilize caspase-8 at the DISC, inhibit E3 ligases, to effectively inhibit 
cancer growth and induce apoptosis, DISC stabilizing molecules or even caspase-8 dimer 
inducing molecules (Figure 4.1.1).   
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Figure 4.1.1 Translational significance of Caspase-8 Studies 
  
81 
 
Figure 4.1.1: Translational Significance of Caspase-8 Studies 
 
This schematic diagram illustrates the potential mechanism of action regarding the three 
possible clinically significance therapies as a result of further defining caspase-8 
regulation.  These strategies can be used to over-come Velcade resistance by eliciting the 
same effect observed when Velcade and TRAIL are used in combination for treatment of 
cancer. .,  mnnn 
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                                           Chapter 5 Future Directions  
5.1 Caspase-8 Polyubiquitination  
 One of my early tasks in my doctoral studies was to analyze HA-tagged caspase-8 
fragments and determine which region of caspase-8 was polyubiquintated. This task 
entailed generating an HA-tagged version of each of the caspase-8 subunits (Fig. 5.1 
panel A). Once generated, these constructs were transfected into PC3 cells which were 
treated with or without Velcade and expression was evaluated through Western blot. The  
p20, and p18 fragments demonstrated a banding / smear pattern that was indicative of 
polyubiquitination. Originally we thought maybe the p2 is conferring some sort of 
stabilization to the p18, however, the data showed that the  p20 (p18+p2) possessed a 
banding/smearing pattern indicative of polyubiquitination Another interesting finding 
was that p30 (p18, p2, p10) was stable with or without proteasome inhibitor, providing 
another piece of evidence suggesting that caspase-8 processing is required for 
polyubiquitination.  
One of the major caveats to this study is the fact that these are over-expressed 
caspase-8 fragments, granted they provide insight into ubiquitination but the 
physiological relevance comes into question.  However, this data provided us with a 
better understanding and prompted us to evaluate cleaved vs. intact caspase-8 
polyubiquitination status in endogenous caspase-8 using our prostate cancer cell models.  
These experiments also set us up for the next component of the project which was to 
identify the amino acid residues within the p18 subunit that were polyubiquitinated.  
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5.2 Identification of Ubiquitinated Amino Acids in Caspase-8 and Determination of 
the Apoptotic Action of Stabilized Caspase-8 Mutants. 
Our goal was to further interrogate caspase-8 ubiquitination and attempt to define 
which lysine residues were being covalently linked to ubiquitin. To accomplish this goal 
our strategy involved first identifying the polyubiquitinated lysine residue(s) within the 
p18 subunit. Once identified, the residue will be mutated, reintroduced into caspase-8 
deficient cells and then effect on apoptosis examined. The first objective is to identify the 
amino acids of caspase-8 that control ubiquitination by mass spectrometry (MS). To 
obtain enough protein for analysis we devised a strategy to tag caspase-8 with a 
hemagglutinin (HA) epitope. A p18HA construct (in addition various other fragments as 
controls) was expressed in LNCaP cells. Cells were treated with or without proteasome 
inhibition and examined by Western blotting. The pro-domain and p30 fragment 
(containing the uncleaved C-terminus) were readily expressed without proteasome 
inhibition (Fig. 21A), however the p18 and p10 fragments required proteasome inhibition 
for expression.  
Furthermore, a high molecular weight smear is a characteristic of 
polyubiquitination, and this was only observed with the p18HA and p20HA fragments. 
Therefore, we felt confident that the overexpressed p18HA construct could be purified 
and the polyubiquitinated residues could be identified using MS.  The strategy to identify 
these residues involved using overexpressed p18HA in cells in the presence of 
epoxomicin. Two steps will be used to purify ubiquitinated p18HA, the first,  total p18 
was to be isolated using an anti-HA-agarose conjugated antibody (Santa Cruz industries) 
and the second step involved using the polyubiquitin enrichment kit (Pierce) to pull down 
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polyubiquitinated p18HA. This second pull down ensured only polyubiquitinated 
caspase-8 p18-HA species was processed and prepared for mass spectrometry analysis.  
The polyubiquitinated p18HA protein mass spectrometric analysis will be 
performed at the University of Kentucky Center for Structural Biology Protein Core 
Facility in our Department. Briefly, the sample will be treated with trypsin to create 
peptide fragments. Trypsin cleaves after Arg and Lys residues. Studies have shown that 
ubiquitination sites can be identified using MS, by taking advantage of the fact that 
isopeptide-linked ubiquitin is cleaved by trypsin at between Arg 74 and Gly 75, 
producing a GG signature peptide with 114.04 Da of extra mass (29). The peptides will 
be desalted and analyzed by MALDI TOF. Peptide mass data will be compared to the 
predicted 18HA peptide masses. As each peptide will contain one lysine residue, we will 
conclude any peptide with an additional 114.04 will be a polyubiquitination site. 
Access to the mass spectrometry facilities and the guidance and expertise of Dr. 
Haining Zhu, Director of the Structural Biology Protein Core in the Department of 
Biochemistry, facilitated the successful completion of these studies. The issue is that the 
p18HA subunit is not physiologic and may yield non-physiologic polyubiquitination of 
residues not normally polyubiquitinated, in a physiologically-relevant setting. An 
alternative strategy involves performing the described IP steps using LNCaP cells and 
scaling up until we are able to pull down enough polyubiquitinated caspase-8 required for 
mass-spectrometry (MS). 
A second important objective was to select an appropriate system to study mutant 
caspase-8 constructs for stability, activity, and apoptosis induction. We sought to use a 
caspase-8 deficient cell line as an expression system because this characteristic offers the 
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advantage of collecting and evaluating expression and functional data of our constructs 
without having to take endogenous caspase-8 into consideration. Unfortunately, caspase-
8 deficient prostate cancer cell lines do not exist. However, I9.2 caspase-8 deficient 
Jurkat-derived cell line and NB7 neuroblastoma cell lines are perfect candidates as both 
can induce apoptosis via TRAIL stimulation upon caspase-8 reconstitution.  Evidence 
from unpublished data indicates that the caspase-8 expressing Jurkat cell line behaved 
similarly to PC-3 human prostate cancer cells, in terms of caspase-8 cleavage, p18 
stability, and the apoptotic response to proteasome inhibitor and TRAIL treatment. To 
confirm the ability of I9.2 cells to undergo TRAIL-mediated apoptosis upon restoring 
caspase-8 these cells were transduced with a pBABE-puro encoding wild-type caspase-8. 
Following puromycin selection, comparisons were made between I9.2 reconstituted 
caspase-8 (I9.2 RC8), I9.2 puro against the wild-type Jurkat, and I9.2 cell lines to assess 
caspase-8 expression, cleavage and TRAIL induced death via Western blot and MTT 
assay (Figure 23C). The results showed the I9.2 puro and I9.2 RC8 behaved identically to 
wild-type cell lines. Therefore, we felt that this model could be used as a tool to study the 
effect of ubiquitination-defective caspase-8 constructs on apoptosis. 
The goal was to reconstitute ubiquitination-defective caspase-8 mutant constructs 
into the caspase-8 deficient I9.2 cells to generate stable caspase-8 expressing cell lines. 
Once we have identified the ubiquitinated lysine residue(s) then we can proceed with site 
directed mutagenesis, converting the lysine residue to arginine (KR). The pGEM 
shuttle vector encoded with wild-type caspase-8 will be used to generate the mutant 
forms of caspase-8 and once mutations have been verified by restriction digest, the 
mutant caspase-8 construct will then be subcloned into pBABE expression vector. After 
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confirming the sequence is correct, the caspase-8 mutant construct will then be 
introduced into the Jurkat I9.2 system. We  transduced I9.2 caspase-8 deficient cells with 
the pBABE puro caspase-8 mutant expressing vectors by following the same procedures 
used to generate the I9.2 wild-type caspase-8 expressing cell line as explained in the 
preliminary data. After having reconstituted and selected for the I9.2 cells expressing our 
mutant caspase-8 construct, using Western blot to confirm caspase-8 expression. Annexin 
V staining will be performed following the treatment of the I9.2 KR caspase-8, RC-8 
wild-type caspase-8, and I9.2 puro cell lines with TRAIL to assess apoptosis. The 
University of Kentucky Flow Cytometry Facility will analyze the staining. All assays will 
be carried out in triplicate and statistical comparisons between the KR caspase-8 and 
RC8 control cells carried out with a pair-wise Student’s t test. Additionally, we will use 
immunoprecipitation/Western blotting to assess association between ubiquitin and 
caspase-8 KR mutants. It is anticipated that the KR mutations will reduce and/or 
abolish polyubiquitination of the p18 fragment. One of the potential difficulties may be 
that regardless of the KR mutations, the p18 may still be subjected to ubiquitination (as 
a result of site shifting) and proteasome degradation. To address this problem we could 
subject the constructs to the same IP/Mass Spectrometry conditions to determine which 
amino acid is being ubiquitinated. After identifying the ubiquitinated lysine residues we 
can then carry out site directed mutagenesis and test the new construct for caspase-8 as 
outlined above. Additionally, there is the potential that the KR mutations may confer 
p18 stability but may result in catalytically inactive form of caspase-8. Studies may 
involve comparing caspase-8 stability via the half-life assay caspase-8 activity between 
wild-type Jurkat and I9.2 RC8 using the caspase-8 GLO activity kit. After reconstituting 
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caspase-8 in the I9.2 caspase-8 deficient cells, and performing a series of experiments 
with those clones their maintenance presented serious challenges.   Several attempts were 
made to generate these caspase-8 expressing I9.2 lines again, the  problem encountered 
generating these cell lines, was the large number of false positive cells.  The pLSG vector 
is an excellent vector to use with retroviral transduction strategies because these vectors 
have EFGP that are linked to LTR while the promoter for the protein of interest is an 
SV40. However, the issue arises that EGFP expression and the protein of interest 
expression were not linked in some fashion, leading to strong EGFP expression but not 
caspase-8 expression. One potential solution to overcome these difficulties is to use an 
inducible promoter system, however, this meant that multiple constructs would have to be 
introduced via transduction methods.  My goal at this point was to identify a caspase-8 
deficient cell line that were responsive to either TNF-α or TRAIL  and of the many 
caspase-8 deficient cell lines, only the NB7 and the I9.2 showed apoptosis induction with 
either ligand.   
In our pursuit for a suitable caspase-8 deficient cellular tool, we continued using 
LNCaP cells to determine if it would be possible to acquire enough caspase-8 p18 to use 
for mass spec.  This goal was addressed by performing several caspase-8 experiments 
using several different conditions that maximized caspase-8 processing and p18 yield 
with the pull down.  Unfortunately, through our efforts we were incapable of pulling 
down sufficient amounts of processed p18 subunit.  Another alternative was to perform a 
set of IP experiments pulling down the p18-HA construct as this construct had good 
expression and revealed polyubiquitin smears on a normal Western blot (Fig.1 panel  b   
B). Although the pull-down was successful and we could see the p18 subunit, we were 
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unfortunate and failed to observe any polyubiquitin smears (data not shown).  It was 
critical to use the free standing p18 subunit rather than rely on the p43/41 subunit at the 
membrane because with the free standing p18 we were looking at one specific 
component.  Using the p43/41, this would require removing the DISC components which 
would complicate the mass spec results.   Having acquired the NB7 cells and the caspase-
8 mutant constructs from Dr. Doug Green’s, provided promise for picking up and 
completing these experiments at a later time once we resolve the issue with having 
enough polyubiquitinated p18 to analyze via mass spec.  Despite these caveats this 
remains an important pursuit towards understanding caspase-8 regulation because, 
specifically uncovering if can uncover which of the lysine molecules are regulatory, then 
this would allow for the development of a specific molecular inhibitor that would block 
polyubiquitination of these residues (provided there is no polyubiquitin site shifting), thus 
stabling caspase-8.    
 
5.3  Role of E3 ligase POSH and Siah2 in Caspase-8 Activity Regulation 
 from our lab first identified a role for Siah2 and POSH as E3 ligases that played a 
role in regulating caspase-8 activity, however, the mechanism by which caspase-8 
activity was being influenced was not defined(Christian et al., 2011).  There were still 
several avenues to pursue looking at both POSH and Siah2, as I previously mentioned the 
data suggests that although neither E3 ligase impacts caspase-8 processing(Christian et 
al., 2011), I hypothesize that these E3 ligases are impacting caspase-8 trafficking through 
the polyubiquitination of caspase-8 at the DISC triggering the second cleavage event of 
caspase-8 releasing it into the DISC.   
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The rationale for this hypothesis comes from the activity data from both NB7 and 
LNCaP studies. Both studies showed that were significant caspase-8 activity at the 
plasma membrane, in the LNCAP cell lines plasma membrane activity was markedly 
increased over the cytosol while the NB7 cells showed that while the plasma membrane 
had much less activity than the cytosol.  Time course analysis in the LNCaP cancer cells 
clearly indicates a decreased  activity at the plasma membrane after 12 hours of 
TRAIL/Epoxomicin treatment, paralleled by an increase in activity in the cytosol. My 
studies support the notion that the change in activity is attributed to the release of 
caspase-8 from the membrane into the cytosol thus suggesting that the over-all activity 
isn’t changing, just the location. Once the cytosolic pool of processed caspase-8 is 
degraded, then one would observe the decrease in caspase-8 activity however, with the 
addition of proteasome inhibitor, caspase-8 degradation is blocked and this may account 
for the consistent cytosolic increase in caspase-8 activity over time.  The NB7 data 
showed an increase in caspase-8 at the plasma membrane with the D3A and D2A mutants 
compared to wild-type caspase-8 because these constructs are not being released from the 
DISC.  
 Therefore, my goal was to further interrogate POSH using LNCaP cells 
expressing either MYC tagged wild-type or ring mutant POSH.  The initial experiments 
involved using confocal microscopy showed strong co-localization between caspase-8 
and POSH (Fig. 5.3.1) A.  Unfortunately, subsequent repeat experiments failed to show 
any co-localization at all. Next, we examined whether silencing POSH or Siah2 had any 
impact on c-FLIP levels. This is a logical relationship to examine because c-FLIP is an 
inhibitor of caspase-8 processing and can lead to a decrease in caspase-8 activity.  
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Therefore, we hypothesized that c-FLIP levels may be decreased as a result of silencing 
POSH and Siah2.  Siah2 or POSH were silenced and cells were harvested and FLIP 
expression was analyzed via Western blot. There was no real change in expression of c-
FLIP regardless of Siah2 or POSH expression.  We then used yeast two hybrid 
experiments to determine whether c-FLIP, POSH, and Siah2 interacted with one another.  
The positive control was POSH and Siah2 as these two E3 ligases have already been 
shown to interact with one another(Christian et al., 2011). Colonies transformed with 
cFLIP and POSH failed to grow on selection medium which indicated that there was no 
interaction between cFLIP and POSH. 
  I subsequently conducted a series of immunoprecipitation experiments to 
determine the association between caspase-8 and MYC-POSH.  Unfortunately the 
outcomes were negative in terms of revealing association.  Next I employed various 
immunoprecipitation techniques to reveal look an association between POSH and 
potential following TRAIL / proteasome inhibitor stimulation.  To ensure clean pull-
downs and circumvent antibody contamination, we used the uMACS epitope tag isolation 
kit that was specific for MYC tags.  Although we were successful in pulling down POSH 
using MYC antibodies and with the uMACS pull-down kit we were unsuccessful in 
finding any binding partners in either non-treated or TRAIL/Epoxomicin treated samples.  
 This specific project was put on hold for several reasons (including effort and 
time constraints), many critical avenues beg exploration of the contribution by POSH and 
Siah2 in the apoptotic signaling. Considering the evidence that neither POSH nor Siah2 
impacts caspase-8 processing (Christian et al., 2011).  The fractionation activity data 
provided the rationale that these E3 ligases modulate caspase-8 activity by triggering 
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caspase-8 release from the DISC by polyubiquitination.  The data showed that caspase-8 
activity accumulated over time up till 8 hours after which there was a sharp decrease in 
the plasma membrane and an increase in cytosolic caspase-8 activity at 12 hours. This 
activity ties into the polyubiquitination pull-downs because caspase-8 was shown to be 
polyubiquintated at 8 hours. Therefore, this suggests that following the initial cleavage 
event, caspase-8 may be polyubiquitinated thus, triggering the second cleavage event that 
releases caspase-8 into the cytosol to be degraded.   
To address this hypothesis, subcellular fractionation assays can be performed 
following POSH and Siah2 silencing  to evaluate caspase-8 processing and observe any 
changes in caspase-8 remaining at the DISC and if its release is delayed as a result of 
knocking down POSH and Siah2.  POSH and Siah2 may be polyubiquitinating caspase-8 
at the DISC and while processing isn’t altered in the respect of degradation, caspase-8 
trafficking from the DISC to the cytosol is what’s being affected.  Therefore, when Siah2 
or POSH were knocked down, the increase in activity could have been the result of 
caspase-8 remaining at the DISC and its released was delayed by the lack of POSH and 
Siah2 expression.  To test this hypothesis, the experiment would involve using a set of 
LNCaP cells that stably over-expressed either POSH and Siah2, as well as a set of cells 
that were transfected with siRNA targeting either POSH or Siah2.  Cells would be either 
non-treated or with TRAIL and epoxomicin (separately or in combination) and evaluate 
caspase-8 expression via Western blot and activity via Caspase-8 GLO kit.  I would 
expect that the cells over-expressing POSH and Siah2 would have elevated caspase-8 
activity levels and expression in the cytosol compared to the plasma membrane while the 
reverse should hold true for the POSH and Siah2 knockdown lines. Additional functional 
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studies in LNCaP human prostate cancer cells and/or the NB7 caspase-8 expressing cells, 
would involve silencing or over expressing of Siah2, and POSH via transfections, and 
treatment of stable clones with either TRAIL and/or Epoxomicin. Ubiquitin pull-down 
experiments would subsequently identify the functional involvement of these E3 ligases 
in the regulation of caspase-8 polyubiquitination.   
It would be critical to determine if there is any change at all caspase-8 activity by 
polyubiquitination, regardless of the expression status of POSH and Siah2, thus defining 
the role of E3 ligases as major control players in the process.  Other potential players 
besides these E3 ligases may mediate caspase-8 polyubiquitination.  Identifying this E3 
ligase could be pursued by using a method similar to the reverse siRNA library approach 
we employed, the difference is that Dharma-con has new all-encompassing E3-ligase 
screens that go beyond the 239 E3 ligase limit with the prior screen.   
Chemotherapeutic strategies involving caspase activating or stabilizing molecules 
have been emerging in the last few years. Caspase-9 studies have revealed that FKBP-
catalytic caspase-9 subunit conjugates are capable of dimerizing to one another resulting 
in an active caspase-9 (iCasp9). This fusion, iCasp9 is capable of inducing apoptosis as 
demonstrated with in-vitro and in-vivo prostate cancer models (Xie et al., 2001). Further 
studies have shown iCasp9 is capable of inducing apoptosis in chemotherapeutic resistant 
colorectal cancer stem cells (Kemper et al., 2012). Recent evidence indicates that small 
molecules like PAC-1, are capable of inducing caspase-3 activation independent of 
mitochondrial or extrinsic pathway stimulation using in-vitro and in-vivo models (Putt et 
al., 2006).    
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Despite the exciting promise surrounding these emerging strategies, they too are 
limited to those cancer types capable of having functional apoptotic machinery. 
Identifying caspase-8 regulatory molecules would provide the capability of over-coming 
some of the barriers mediating apoptosis resistance such over-expression of the pro-
survival players that would inhibit caspase-9 activation. Additionally, it may be possible 
to use the caspase-8 stabilizing agents with TRAIL to produce the same cancer cell 
specific apoptosis induction as observed with TRAIL and Velcade, without having the 
associated side effects associated with Velcade and general proteasome inhibition. The 
rationale for this concept is based on the fact that caspase-8 is only processed upon 
stimulation with death receptor ligands, and TRAIL has been demonstrated to induce 
apoptosis in cancer cells.   
 The significance of this work surrounds the identification of new caspase-8 
regulatory molecules that will provide new attractive targets for a development of a 
molecular therapeutics platform exploiting key players in the pathway. This ultimately 
would lead to generation of effective inhibitors against caspase-8 stability, leading to 
apoptosis induction in cancer cells, while circumventing the caveats associated with 
current chemotherapeutic strategies in the management of cancer patients.  
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Figure 5.1.1: Experimental Flow Chart and Construct Design.   
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Figure 5.1.1: Experimental flow chart and construct design.  
 HA-tagged fragments of caspase-8 were to be subcloned into pBABE expression vector, 
used for transient transfection into PC3 cells. Cells were treated with or without Velcade 
and expression was evaluated via Western blot.  
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Figure 5.1.2. Caspase-8 Autoprocessing Confers Dependence on Proteasome Inhibition 
for Expression and Suggests that the p18 Subunit is Polyubiquitinated.  
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Figure 5.1.2. Caspase-8 autoprocessing confers dependence on proteasome 
inhibition for expression and suggests that the p18 subunit is polyubiquitinated. A 
Western blot showing the p30 fragment of caspase-8 can be expressed without 
proteasome inhibitor. B) Upon cleavage of the p30, the p10 and p18 fragments require 
proteasome inhibitor to see expression. C). Comparison of pro-fragment, p20, and p12 
fragments for short(1min) and longer (7min) exposures   
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Figure 5.2.1. Caspase-8 re-expression in caspase-8 deficient I9.2 Jurkat cells. 
  
A 
.  
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Figure 5.2.1. Caspase-8 re-expression in caspase-8 deficient I9.2 Jurkat cells. A.) Pull 
down caspase-8 polyubiquitinated p18 subunit, identify the polyubiquitinated lysine 
residues.  B). Identified lysine residues within the p18 subunit were to be mutated to 
Arginine, followed by subcloning into pBABE or pLSG expression vectors to generate 
stably caspase-8 mutant expressing cell lines to evaluate the contribution of 
polyubiquitination to caspase-8 regulation.  C). Reconstitution of caspase-8 in I9.2 
caspase-8 deficient Jurkat cells. 
.  
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Figure 5.3.1 Results of POSH studies.   
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Figure 5.3.1 Posh Localization Studies 
A. Co-localization studies showing co-localization status between Caspase-8 and POSH. 
B. Western blot demonstrating c-Flip expression as a result of POSH and SIAH2 
knockdown. C. Western blot demonstrating successful expression of POSH-MYC. 
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 Appendix 
 
1. Symbols 
a. Alpha, α 
b. Beta, β 
c. Gamma, γ 
d. Kappa, κ 
e. Mu, μ 
 
Abbreviations:  
Immunoprecipitation (IP)  
Propidium Iodide, (PI) 
TNF-alpha Related Apoptosis Inducing Ligand (TRAIL)  
Histone Deacetylase 7 (HDAC7) 
Death Inducing Signaling Complex (DISC) 
Fas associated Death Domain (FADD) 
 Neuroblastoma 7 (NB7)  
Glutathione S-transferase GST  
Tumor, Necrosis Factor-α (TNF-α),  
American Type Culture Collection (ATCC),  
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)),  
Castration-recurrent prostate cancer (CRPC) 
Allophycocyanin (APC) 
Cell lines 
Prostate Cancer Cell lines 
LNCaP 
DU145 
PPC-1 
PC-3 
T Cell lines 
Jurkat 
I9.2 Jurket 
Lung Cancer Cell line 
H460 
Breast Cancer Cell line 
MCF-7 
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